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ABSTRACT 
Homocysteine (Hcy) and C-reactive protein (CRP) are established risk factors for 
atherosclerotic cardiovascular disease and are emerging as novel risk factors for osteoporosis. 
The primary purpose of this study was to determine whether total Hcy and CRP 
concentrations are associated with trabecular and/or cortical bone mineral content (BMC) or 
bone mineral density (BMD) in postmenopausal women. The secondary objective was to 
determine the body composition and nutritional status indices (dietary and circulating) and 
key biologic factors related to total Hcy and CRP. The tertiary purpose of this study was to 
examine changes in total Hcy and CRP over one year. We enrolled healthy postmenopausal 
women (N=242) as part of a randomized, double-blind, placebo-controlled multi-center 
clinical trial designed to examine the effect of two doses of soy isoflavones on bone loss over 
three years in early postmenopausal women. This study assessed volumetric BMD at the 
distal tibia and femur (1 /3 site) using peripheral quantitative computed tomography (pQCT) 
in a subset of women (N=184 for distal tibia; N=237 for 1/3 femur site). Total Hcy and CRP 
did not contribute to the variability in trabecular BMC of the distal tibia or cortical BMC of 
the 1/3 femur site using pQCT. Approximately 22% of the variability in trabecular BMC was 
accounted for by weight, hemoglobin, serum uric acid, and blood glucose. Study site, weight, 
and age accounted for about 14% of the variability in cortical BMC. The overall variability 
(19%; p<_0.0001) in total Hcy was accounted for by serum vitamin B 12 and creatinine; the 
overall variability (28%; p<_0.0001) in CRP was accounted for by serum iron, overall percent 
body fat, serum uric acid, triglycerides, and white blood cell count. Total Hcy and CRP 
increased, while serum vitamin B 12, serum folate, and intracellular folate decreased over a 
one year period. Total Hcy and CRP were not related to trabecular or cortical bone, but this 
may be because these women were healthy and non-osteoporotic. Since hemoglobin was a 
significant contributor to trabecular BMC, while iron was a significant contributor to CRP, it 





This thesis begins with a general introduction describing the objectives, hypothesis, 
specific aims, limitations, and significance of this research project. 
Objectives 
The first objective of this study is to determine whether total homocysteine (Hcy) and 
C-reactive protein (CRP) concentrations are associated with trabecular and/or cortical bone 
mineral content (BMC) while taking into account key biologic factors in postmenopausal 
women. The second objective is to identify various factors (key biologic and nutritional 
status indices) related to total Hcy and CRP. The tertiary objective is to determine whether 
total Hcy and CRP change during the course of one year. The long-term objective is to 
pursue anon-pharmacologic approach to reducing disease risk in women after menopause. 
Hypotheses 
1) At baseline, total Hcy is inversely related to trabecular BMC in postmenopausal 
women, while taking into account key biologic factors. 
2) At baseline, CRP is inversely related to trabecular or cortical BMC and BMD in 
postmenopausal women, while taking into account key biologic factors. 
3) At baseline, adiposity, indices of nutritional status (dietary intake and circulating 
analytes), and key biologic factors are significantly related to total Hcy and CRP. 
4) During the course of one year, total Hcy increases whereas CRP does not change in 
postmenopausal women. 
Specific Aims 
1) To determine whether plasma total Hcy is inversely related to trabecular BMC of the 
distal tibia using peripheral quantitative computed tomography (pQCT) in 
postmenopausal women, taking into account key biologic factors, particularly folate 
and vitamin B 12 status. 
2) To determine whether serum CRP is inversely related to trabecular BMC of the distal 
tibia and/or cortical BMC of the 1/3 femur site using pQCT in postmenopausal 
women, taking into account key biologic factors. 
nL 
3) To identify the body composition, nutritional status indices (dietary and circulating), 
and key biologic factors related to total Hcy and CRP. 
4) To examine whether total Hcy or CRP change over the course of one year. 
Limitations 
The first limitation is that we have only included for the pQCT data about half of the 
women from the UC-Davis site because of incorrect data acquisition. The second limitation 
is that there is more variability in some of the data from UC-Davis for the outcomes of 
interest and their corresponding contributing factors. The design of the study is to determine 
the effect of two doses of isoflavones (80 and 120 mg) on total Hcy concentration, taking 
folate and B 12 into account. However, the third limitation of this study is that we will not be 
able to unblind the investigators until we have completed the intervention at both study sites 
in 2008. Thus, statistical analyses for the treatment effect will be completed in 2008. 
Significance 
The menopausal transition is characterized by a rapid decline in ovarian function and 
a subsequent decline in circulating hormones, including estradiol. This hormone-deficient 
state contributes to significant risk for developing osteoporosis (Scheiber and Rebar 1999) 
and CVD (Welty 2001) in postmenopausal women. Some research has related high total Hcy, 
common after menopause (Hak et a1. 2000), to a decrease in BMD. However, no studies have 
examined the effect of total Hcy on trabecular and cortical bone separately. This is of 
primary importance as trabecular bone reflects metabolically active bone, which is 
preferentially lost during menopause and thus is of interest in assessing early osteoporotic 
risk (Takagi et al. 1995). Additionally, at the time these data were analyzed, no studies had 
been published on the association between CRP and bone loss associated with menopause. 
Similar to atherogenesis, osteoporosis has an inflammatory component, thus providing the 
biological plausibility for the potential use of CRP, a proinflammatory risk factor for CVD, 
as a marker of osteoporotic risk. 
Data on the effect of soy isoflavones on total Hcy and CRP in postmenopausal 
women are limited and inconsistent. Published studies have examined the relationship 
between total Hcy and BMC and BMD, but have not distinguished between cortical and 
trabecular bone. Further, there are no long-term studies published that have assessed the 
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response of two doses of isoflavones on these two markers of CVD and osteoporotic risk 
(specifically trabecular bone) in postmenopausal women. This study will determine the effect 
of two doses (80 and 120 mg) of isoflavones on total Hcy and CRP concentrations in relation 
to change in trabecular bone. 
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REVIEW OF LITERATURE 
A. CONSEQUENCES OF MENOPAUSE: CARDIOVASCULAR DISEASE AND OSTEOPOROSIS 
Atherosclerotic CVD and osteoporosis are major public health problems that often 
coexist and account for significant morbidity and mortality in postmenopausal women. The 
postmenopausal period typically occupies one-third of a woman's life, with more than 40 
million in the United States now in the postmenopausal phase (Hargrove and Eisenberg 
1995). Menopause is a transitional phase in a woman's life, where loss of ovarian function is 
marked by cessation of menstruation and reproductive capability (World Health Organization 
1981). It is this decrease in estrogen that places postmenopausal women at increased risk of 
atherosclerotic CVD and osteoporosis. Although traditionally thought of as separate disease 
entities, accumulating evidence indicates that there are similar pathophysiological 
mechanisms underlying CVD and osteoporosis. In addition to age and menopause, other risk 
factors for CVD, such as dyslipidemia, oxidative stress, hyperhomocysteinemia, 
hypertension, and diabetes, have also been associated with low BMD (McFarlane et al. 
2004). Thus, novel forms of therapy that effectively treat both CVD and osteoporosis hold 
considerable promise for the postmenopausal woman who is at an increased risk for these 
diseases. 
In the United States, 500,000 women die each year due to atherosclerotic CVD; one 
out of nine women aged 45-63 years and one out of three women older than 65 years suffer 
from ischemic events caused by atherosclerosis (Gensini et al. 1996}. The incidence of 
atherosclerotic CVD is much lower in premenopausal women compared to their male 
counterparts, suggesting that premenopausal women are somewhat protected. The rate of 
mortality in men from CVD is five to eight times higher than women during ages 25-55 years 
(Ryan 1976), with this difference narrowing considerably after menopause. This suggests 
that premenopausal women have protective vascular/endothelial factors that are lost after 
menopause (Dimitrova et al. 2002). Circulating 17 ~-estradiol, the most biologically active 
form of estrogen, declines during the menopausal transition. 17~i-Estradiol selectively 
enhances endothelium-dependent coronary vasodilation by enhancing the bioavailability of 
nitric oxide (Guetta et al. 1997), a potent coronary vasodilator and a suppressor of several key 
5 
processes in atherosclerosis. 17(3-Estradiol also acts as an antioxidant at the molecular level 
by improving the nitric oxide/free oxygen radical ratio and normalizing the expression of 
proatherosclerotic gene products in human endothelial cells (Wagner et al. 2001). The 
atheroprotective effect of estrogen is also partially attributable to its modulating effect on the 
lipid profile, with changes being evident in postmenopausal women. After menopause, 
women have significantly higher concentrations of total cholesterol, triglycerides, and low 
density lipoprotein cholesterol (LDL-C) (Stevenson et al. 1993) and lower concentrations of 
high density lipoprotein cholesterol (HDL-C). Additionally, changes in body composition 
with increased waist circumference and abdominal fat place menopausal women at increased 
risk by contributing to impaired lipoprotein profiles (Berg et al. 2004). 
Osteoporosis and low BMD are currently a major public health threat to more than ~~I 
million Americans aged 50 or older. Currently in the United States, 10 million people have 
osteoporosis and 80% of these are women (National Osteoporosis Foundation 2002). 
Osteoporosis is defined as a "disease characterized by low bone mass and microarchitectural 
deterioration of bone tissue leading to enhanced bone fragility and a consequent increase in 
fracture incidence" (Melton and Riggs 1983). The World Health Organization has developed 
an operational definition of osteoporosis based on the BMD of young adult Caucasian 
women (Melton 2000). The World Health Organization defines osteoporosis as a BMD less 
than 2.5 standard deviations (SD) below the mean for young women. The World Health 
Organization defines osteopenia as a BMD between 1 and 2.5 SD (also referred to as t-score) 
below the mean for young women. A t-score ranging from -1 SD below the mean or any 
value greater than this indicates normal BMD. 
Menopause, which is essentially ahormone-deficient state, contributes to significant 
risk for developing osteoporosis in postmenopausal women (Scheiber and Rebar 1999). Bone 
loss occurs most rapidly during the years immediately after menopause (Ahlborg et al. 2001); 
in the five to seven years following menopause, women can lose up to 20% of their BMD 
(National Osteoporosis Foundation 2002). Several bone-protective actions exerted by 
estrogen include increased synthesis of 1,25(OH)2 vitamin D, control of bone-resorbing 
cytokine production, and decreased bone sensitivity to parathyroid hormone. 
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B. HOMOCYSTEINE METABOLISM 
Homocysteine (Hcy) is asulfur-containing amino acid and is a metabolite produced 
indirectly in the demethylation of methionine (Figure 1). Hcy is itself metabolized by two 
pathways: the re-methylation pathway, which regenerates methionine, and the 
transsulfuration pathway, which converts Hcy to cysteine and then to taurine. In the 
remethylation pathway, N-5-methyltetrahydrofolate or betaine donates a methyl group to 
Hcy to form methionine. The methionine synthase reaction with N-5 methyltetrahydrofolate 
is vitamin B 12 dependent and occurs in all tissues, while the reaction with betaine occurs 
mainly in the liver and is vitamin B 12 independent. After remethylation, methionine is 
reutilized to produce S-adenosylmethionine (SAM), a universal methyl donor. S-
adenosylhomocysteine, the by-product of these trans-methylation reactions, is subsequently 
hydrolyzed, thus regenerating Hcy. In the transsulfuration pathway, Hcy condenses with 
serine to form cystathionine in an irreversible reaction catalyzed by cystathionine ~3-synthase, 
a vitamin B6 dependent enzyme. cystathionine is further metabolized to cysteine and a-
ketobutyrate. Excess cysteine is then oxidized to taurine or inorganic sulfates and is excreted 
in the urine. The transsulfuration pathway effectively catabolizes excess Hcy, which is not 
required for methyl transfer (Selhub 1999). This pathway has a limited distribution and is 
found primarily in the liver, kidney, small intestine, and pancreas (Finkelstein 2000). 
Several studies have shown that the Hcy metabolic pathways are nutritionally 
regulated. The remethylation and transsulfuration pathways are coordinated by SAM, which 
acts as an allosteric inhibitor of the methylenetetrahydrofolate reductase (MTHr'll) and as an 
activator of cystathionine ~3-synthase enzymes. It is also thought that the utilization of SAM 
is regulated specifically by a reaction in which the methyl group of SAM is transferred to the 
amino group of glycine, forming sarcosine. This reaction is catalyzed by glycine N-
methyltransferase, which is strongly inhibited by N-S-i~nethyltetrahydrofolate polyglutamates 
(Selhub 1999). When dietary methionine is high, it is rapidly converted to SAM resulting in a 
rise in intracellular SAM concentrations. This causes (a) inhibition of MTHr`k, resulting in 
suppressed N-S-methyltetrahydrofolate synthesis, thereby allowing full activity of glycine N-
methyltransferase, and (b) activation of cystathionine ~i-synthase, thus increasing the rate of 





































































































inhibition of MTHFR, resulting in increased concentrations of N-S-methyltetrahydrofolate 
production. These increased concentrations increase the inhibition of glycine N-
methyltransferase and thereby conserve SAM and increase the availability of substrate for 
Hcy remethylation (Selhub 1999). Recent work in five healthy men showed that a diet 
containing low methionine (5 mg/kg/d; RDA for methionine = 21 mg/kg/d) and excess 
dietary cysteine (19 mg/kg/d; RUA for cysteine=ll mg/kg/d) reduced the transsulfuration 
pathway by 81%compared to a diet containing excess methionine (24 mg/kg/d). This 
suggests that at high methionine intakes, the methionine pool is regulated by high rates of 
transsulfuration. Replacement of dietary methionine with cysteine results in increased 
remethylation at the expense of the transsulfuration pathway (Di Buono et al. 2003). 
Hcy concentrations are partly controlled by genetics. Polymorphisms in genes 
encoding for enzymes involved in the metabolism of Hcy may alter the factors affecting 
circulating total Hcy concentrations. For example, in homozygotes for the MTHFR C677T 
mutation, riboflavin status may affect Hcy metabolism, but only in those who have a low 
folate status (Jacques et al. 2002). In these individuals, approximately one to three percent of 
the US population, riboflavin status may be a major determinant in preventing 
hyperhomocysteinemia, while it does not appear to be a significant contributor in the general 
population. Unlike the MTHFR polymorphism, methionine synthase and methionine 
synthase reductase gene polymorphisms do not affect total Hcy concentrations (Jacques et al. 
2003). Lifestyle modifications in populations with the different MTHFR genotype subgroups 
do not alter total Hcy concentrations (Husemoen et al. 2006). 
C. C-REACTIVE PROTEIN METABOLISM 
C-reactive protein (CRP) is an acute phase protein produced by hepatocytes, 
stimulated by systemic inflammation, and is marker of inflammation. CRP is a member of 
the pentraxin family of innate immune response proteins (Bassuk et al. 2004). Although it is 
synthesized as a monomer, the endoplasmic reticulum assembles CRP into a pentamer. In the 
resting state, CRP is bound to carboxylesterases in the endoplasmic reticulum of hepatocytes. 
Upon stimulation, binding to carboxylesterase sites is decreased and the transit time from the 
endoplasmic reticulum to secretion is substantially diminished. As a result of enhanced 
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synthesis and secretion, an acute elevation in CRP is apparent. The concentration of CRP 
increases from less than 1 to as high as 600-1000 mg/L during an acute phase response (Du 
Clos and Mold 2004). In contrast to an acute phase response, results from autopsies of 302 
men and women without inflammatory conditions other than atherosclerosis, during an acute 
rupture of plaque, revealed that the serum CRP was 3.2 compared with 2.5 µ,g/mL in those 
who had stable plaque (Burke et al. 2002). 
Although traditionally thought to be produced in the liver in response to interleukin-6 
(IL-6), mounting evidence now shows that key inflammatory markers, including CRP and 
associated complement proteins, are synthesized in human coronary artery smooth muscle 
cells (Calabro et al. 2003) and atherosclerotic lesions (Yasojima et al. 2001). Recently, 
Meuwissen and others (2006) stated that CRP, macrophages, and oxidized low-density 
lipoprotein (LDL) are present in a higher proportion of plaque from patients with myocardial 
infarction and unstable angina compared to patients with stable angina. This suggests that 
these surrogate markers have important proinflammatory effects within atherosclerotic 
plaques. Calabro and coworkers (2005) demonstrated that human adipocytes also produce 
CRP after stimulation with inflammatory cytokines IL-1 ~3 and IL-6 and by a specific 
adipokine, resistin, thereby suggesting a link between obesity and vascular inflammation. 
D. CARDIOVASCULAR DISEASE RISK FACTORS 
1. Established Risk Factors 
Risk factors for atherosclerotic CVD have been long established and are often known 
to occur in combination. Apart from age and gender, the well established risk factors for 
CVD are hypertension (systolic blood pressure >140 mmHg and/or diastolic pressure >90 
mmHg), cigarette smoking, hypercholesterolemia (>220 mg/dL), impaired glucose tolerance 
(two hour plasma glucose >140 mg/dL and < 200 mg/dL with a glucose challenge) or 
diabetes (fasting blood glucose >126 mg/dL), hypertriglyceridemia (>150 mg/dL), and 
obesity (Aizawa et al. 2004; Wilson et al. 1987). According to the Adult Treatment Panel III 
of the National Cholesterol Education Program, the recommended LDL-C goal is <100 
mg/dL in high-risk persons (patients who have coronary heart disease or underlying blood 
vessel disease to the brain or extremities, or diabetes, or multiple risk factors [e.g., smoking, 
1.0 
hypertension] that imposes a greater than 20% chance of experiencing a heart attack within 
10 years; Grundy et al. 2004). The Framingham Heart Study has shown that a decline of 5 
mg/dL in HDL-C increases the risk of CVD in women by 26% and in men by 21% (Wilson 
et al. 1987). Cigarette smoking doubles the risk of CVD in men (56%) but not in women 
(5%). Another risk factor, cardiac enlargement (defined as left ventricular hypertrophy as 
detected by an electrocardiogram) or enlarged heart as determined by a chest x-ray, imposes 
an increased risk of 55% and 110% in women and men, respectively. Other potentially 
modifiable risk factors include abdominal obesity (waist/hip ratio cut-offs of 0.90-0.95 for 
men and 0.83-0.90 for women); psychosocial factors; irregular consumption of fruits or 
vegetables (daily consumption associated with a 30°Io reduction in relative risk) and/or high 
levels of alcohol (>3 times per week); and irregular physical activity (Yusuf et al. 2004). 
Most often, these established risk factors act synergistically to increase CVD risk. For 
example, when the three risk factors of cigarette smoking, increased systolic blood pressure, 
and increased cholesterol concentration are present, the risk increases by 40% in women and 
100°Io in men (Wilson et al. 1987). 
2. Homocysteine and the Cardiovascular System 
A substantial proportion of CVD events occur in individuals without the established 
risk factors discussed above. Thus, the search for additional etiologic agents or novel risk 
factors still continues. Moreover, while the population-attributable risk of the major 
established risk factors is substantial, it is often difficult to distinguish those individuals with 
a moderate baseline risk who might benefit from aggressive risk reduction strategies. 
Therefore, additional tests for novel risk factors to assist in the prediction of CVD risk in 
these individuals may be warranted. In 1969, McCully was the first to propose that an 
elevated Hcy concentration was responsible for widespread vascular lesions in infants with 
hyperhomocysteinemia. He also hypothesized that moderate hyperhomocysteinemia may be 
causally linked to CVD (McCully 1969). It was later postulated that mild to moderate 
elevations of Hcy in the general population predispose individuals to atherosclerosis in a 
manner akin to the classic risk factors (Hackam and Anand 2003). This is of particular 
importance as this risk can be partially ameliorated by a simple therapy with B-vitamins. 
High concentration of Hcy is now recognized as an independent risk factor for CVD. 
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Total Hcy concentrations in postmenopausal women are 7°Io higher than in 
premenopausal women (Hak et al. 2000) due to decreased circulating estrogen. Recently, 
Morris et al. (2000) reported an association of high estrogen concentration with decreased 
mean serum total Hcy concentration, independent of nutritional status or muscle mass. Hcy 
concentrations are lower in pregnant and premenopausal women and in postmenopausal 
women who are on estrogen therapy, compared to postmenopausal women who are not on 
estrogen therapy. Estrogen impacts methionine/Hcy metabolism likely by interfering with the 
transsulfuration pathway. Estrogen prevents Hcy accumulation by enhancing the net 
production of glutathione, which in turn may stabilize nitric oxide, contributing to its 
beneficial effects (Dimitrova et al. 2002). A Canadian study (Masse et al. 2005) in healthy 
women found that the mean fasting plasma total Hcy concentration of the postmenopausal 
group was two-fold higher than that of the premenopausal group (P<0.0001), which remained 
highly significant after adjustment for confounding variables (dietary intake and blood 
concentrations of vitamin B12, vitamin B6, and folate). This further reiterates that the 
postmenopausal increase in total Hcy is due to estrogen deficiency and not due to dietary 
factors. 
a. Epidemiologic evidence for homocysteine and cardiovascular disease 
Numerous observational studies have reported on the association between Hcy 
concentration and CVD risk in both the general population and in those with preexisting 
CVD. Two meta-analyses have appeared in recent years in an attempt to summarize the 
evidence (Wald et al. 2002; Homocysteine Studies Collaboration 2002). Lowering Hcy 
concentrations by 3 µmoUL reduces the risk of ischemic heart disease by 16%, deep vein 
thrombosis by 25°Io, and stroke by 24°Io (Wald et al. 2002). In ameta-analysis of 30 
prospective studies involving a total of 5,073 ischemic heart disease events and 1,113 stroke 
events, after adjustments for known CVD risk factors and regression dilution bias, authors 
demonstrated that a 25 °Io lower Hcy concentration was associated with an 11 %lower 
ischemic heart disease risk and 19°Io lower stroke risk (Homocysteine Studies Collaboration 
2002). Proportional hazards modeling in a large population-based cohort of 1,933 elderly 
(mean age 70 ± 7 years; 58.9°Io women) participants from the original Framingham Study 
cohort revealed that total Hcy concentrations in the upper quartile (> 14.26 µmoUL) compared 
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to the lower three quartiles (<14.2 µmol/L) were associated with similar relative risk 
estimates of 2.18 for all-cause mortality and 2.17 for CVD mortality. Adjustments for various 
risk factors attenuated these associations but they remained significant (Bostom et al. 1999). 
Data from the third National Health and Nutrition Examination Survey (NHANES) 
III, a nationally representative survey of US adults (N=3,173 in this analysis), revealed that 
there was atwo-fold increase in the likelihood of myocardial infarction among persons with a 
total Hcy concentration of >15 µmoUL and this association did not differ by race or ethnicity 
(Giles et al. 2000). The Physician's Health Study involving 14,916 male physicians, aged 40-
84 years revealed that hyperhomocysteinemia ryas associated with increased prospective risk 
of myocardial infarction (Stampfer et al. 1992). In a study of 941 adolescents aged 12-16 
years in the NHANES III trial, serum total Hcy was significantly and positively associated 
with blood pressure in boys (beta=0.21, P=0.03). After adjustment for confounders, parental 
history of high blood pressure or stroke before age 50 was very strongly associated with the 
subjects' serum total Hcy (beta=0.16, P=0.003) (Gillum 2004). 
Although there is an established link between increased Hcy and atherosclerotic CVD 
risk, relatively few studies have been conducted on the effect of Hcy-lowering therapy in 
decreasing risk in patients with CVD. An interesting study by Bonaa et al. (2006) showed 
that Hcy-lowering treatment with folic acid, vitamin B6, and vitamin B12 in 3,749 men and 
women who had experienced an acute myocardial infarction was not effective and in fact 
there was a trend toward increased risk. However, a recent study by Yang et al. (2006) 
revealed that there was an improvement in stroke mortality across all population strata from 
1998 to 2002 (overall change from -0.3% to -2.9% per year; P=0.0005) after folic acid 
fortification in the United States, but not in England and Wales where there was no folic acid 
fortification. This is consistent with the hypothesis that folic acid fortification helps to reduce 
deaths from stroke by reducing Hcy concentrations. 
b. Pathogenesis of hyperhomocysteinemia 
Hyperhomocysteinemia or increased concentration of Hcy could be due to defects in 
genes encoding for the enzymes involved in Hcy metabolism (Table 1). Homocystinuria due 
to cystathionine (3-synthase deficiency, inherited as an autosomal recessive trait, is the most 
prevalent inborn error of methionine metabolism (Kluijtmans et al. 1999). Homozygotes with 
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cystathionine ~3-synthase deficiency have severe hyperhomocysteinemia with Hcy 
concentrations ranging from 100-500 µmol/L (Yang et al. 2005). A common polymorphism 
in the gene coding for the 5,10-MTHN'lZ (C677T, Ala ~ Val) is associated with a decreased 
activity of the enzyme due to thermolability (Cortese and Motti 2001). 
Table 1: Classification of Hyperhomocysteinemia 
Severe hyperhomocysteinemia 
High total Hcy concentrations at all times; caused by deficiencies in CBS, MTHFR, or 
enzymes of B12 metabolism 
Mild hyperhomocysteinemia 
Moderately high total Hcy concentrations under fasting conditions; reflects impaired Hcy 
methylation (folate, B 12, or moderate enzyme defects such as thermolabile MTHFR) 
Adapted from Selhub (1999); CBS — Cystathionine beta synthase, MTHFR — 
methylenetetrahydrofolate reducatse 
The effect of MTHrR thermolability on total Hcy concentration is attenuated in 
premenopausal females and is not significant in subjects who exhibit serum concentrations of 
folate and/or vitamin B 12 above the 50th percentile of the general population (Cortese and 
Motti 2001). Kang et al (1993) demonstrated that MTHFR thermolability is present in 17% 
of patients with established coronary artery disease, but it is not associated with other 
coronary risk factors such as age, sex, diabetes, smoking, hypercholesterolemia, or 
hypertension. Data from 293 Physicians' Health Study participants who developed 
myocardial infarction through eight years of follow-up and 290 control subjects showed that 
MTHr'il polymorphism was not associated with risk of myocardial infarction but with a 
higher Hcy concentration (Ma et al. 1996). However, in acase-control comparison of 711 
vascular disease cases and 747 controls from nine European countries, there was a strong 
graded association between Hcy and vascular risk in all MTHFR genotypes (CC and TT). 
MTHriZ genotype is a key determinant of plasma total Hcy concentrations (Meleady et al. 
2003) . 
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In addition to polymorphisms in genes encoding enzymes involved in Hcy 
metabolism, the less severe forms of hyperhomocysteinemia could also be due to deficiencies 
in vitamins involved in the Hcy metabolic pathway (Table 1) (Selhub 1999). Ebbesen and 
colleagues (2006) found that hyperhomocysteinemia due to folate deficiency caused changes 
in the gene expression of huffy coat cells, characterized by increased platelet activation and 
impaired fibrinolysis. This mechanism explains the increased risk of hyperhomocysteinemic 
patients for thrombosis. In a rat model, folate deficiency increased hepatic glycine N-
methyltransferase activity and decreased liver SAM (Uthus et al. 2006). Several other studies 
demonstrated that hyperhomocysteinemia can be ameliorated by folic acid supplementation 
(Huemer et al. 2005; Racek et al. 2005), while others induced hyperhomocysteinemia in 
experimental animals by feeding a folate deficient diet (Yeh et al. 2006; Ebbesen and 
Ingerslev 2005; Zhang et al. 2004). 
c. Purported mechanisms for homocysteine in atherogenesis 
Elevated circulating Hcy is an independent risk factor for atherosclerotic CVD and 
has an effect over and above that of inflammatory markers and the major cardiovascular risk 
factors (Woodward et al. 2006). A large body of research has demonstrated several different 
biological mechanisms by which hyperhomocysteinemia may be pathologic. Although 
several mechanistic studies have demonstrated significant effects caused by 
hyperhomocysteinemia, several plausible mechanisms have been hypothesized with five 
mayor ones elaborated upon below. 
1) Smooth muscle cell proliferation: In the mid 90's, Tsai and 
colleagues (Tsai et al. 1994) demonstrated in rat aortic smooth cells that Hcy concentration 
of 100 µmol/L and 1000 µmol/L caused DNA synthesis to increase by 25% and 450%, 
respectively. In contrast, elevated total Hcy caused a done-dependent decrease in DNA 
synthesis in human umbilical vein endothelial cells. This growth-promoting effect of Hcy on 
vascular smooth muscle cells, together with its inhibitory effect on endothelial cell growth, 
represents an important mechanism to help explain Hcy-induced atherosclerosis. High Hcy 
concentrations (>100 µmol/L) increase vascular smooth muscle proliferation by increasing 
the synthesis and release of matrix metalloproteinase-2, which is integrally involved in 
vascular remodeling and atherosclerotic plaque destabilization (Doronzo et al. 2005). Cell 
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culture work in rat vascular smooth muscle cells revealed that extracellular folic acid (Guo et 
al. 2006) and copper, but not zinc (Guo et al. 2005), decreased Hcy-induced synthesis of 
matrix metalloproteinase-2 and thus may have a beneficial effect on the pathogenesis of 
atherosclerosis. Qureshi and coworkers (2005) have added that N-methyl D aspartate 
receptors typically found in rat cerebrovascular cells and involved in Hcy uptake also exist in 
vascular smooth muscle cells and appear to mediate, at least in part, Hcy-induced 
dysregulation of vascular smooth muscle cell function. 
2) Endothelial cell damage and dysfunction: Wang et al. (1997) found 
that 10-50 µmoUL Hcy but not cysteine inhibited DNA synthesis in vascular endothelial cells 
and arrested their growth. Later, Zhang and coworkers (Zhang et al. 2001) showed that Hcy 
induced apoptosis in human umbilical vein endothelial cells; the apoptosis was specific to 
Hcy and was not mediated by oxidative stress. In patients with hyperhomocysteinemia, there 
is a decreased number and activity of endothelial progenitor cells, which are involved in 
ongoing endothelial repair (Junhui et al. 2006). This decrease is due to accelerated 
senescence of endothelial progenitor cells through telomerase inactivation (Zhu et al. 2006). 
In a mouse model of carotid injury, Hcy had a profound inhibitory effect on endothelial cell 
proliferation and migration at physiologically relevant concentrations. Also, Hcy inhibited 
endothelial cell adhesion at concentrations of >200 µmol/L, causing impaired 
reendothelialization and increased neointimal formation in severely hyperhomocysteinemic 
mice (Tan et al. 2006). The capacity of Hcy to inhibit proliferation and migration of 
endothelial cells may be responsible for impaired reendothelialization and healing, 
contributing to atherosclerosis in hyperhomocysteinemia. Results from Hcy-treated mouse 
and human aortic endothelial cells suggest that hyperhomocysteinemia impairs endothelial 
function and endothelial nitric oxide synthase activity, primarily through protein kinase C 
activation (Jiang et al. 2005). 
3) Monocyte activation: Cell culture work in primary human 
monocytes (Zeng et al. 2003) and human aortic endothelial cells (Poddar et al. 2001) 
revealed that elevated Hcy concentrations (> 10 µmol/L) increase protein secretion, mRNA 
expression, as well as activity of monocyte chemoattractant protein-1 and IL-8, chemokines 
found in atheromatous plaques. Homocysteine contributes to CVD ri sk through monocyte 
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chemoattractant protein-1 by increasing monocyte chemotaxis into the intima of the arterial 
wall (Sung et al. 2001). 
4) Reactive oxygen species/oxidative stress: Recent work in human 
umbilical vein endothelial cells has shown that the production of reactive oxygen species 
under hyperhomocysteinemic conditions may induce a proinflammatory situation in the 
vessel wall that initiates and promotes atherosclerotic lesion development (Postea et al. 
2006). Incubation of endothelial cells with 100 µmollL Hcy produced a marked elevation of 
superoxide anion in these cells (Au-Yeung et al. 2004) and was regulated by the 
phosphorylation of two subunits of NADPH oxidase (Slow et al. 2006). Although oxidative 
stress is suggested as one of the pathophysiologic conditions underlying the association of 
total Hcy with CVD, work by Huerta et al. (2004) in 123 healthy elderly subjects revealed no 
significant differences in the antioxidant enzymes glutathione peroxidase or superoxide 
dismutase. Also, there were no differences in serum lipid-soluble antioxidants or a marker of 
lipid peroxidation between subjects with elevated plasma total Hcy (>15 µmol/L) as 
compared to those with lower plasma total Hcy. 
5) Vasodilation: Recent work in perfused coronary arteries of rats 
suggests that adenosine plays a role in both the negative inotropic and vasodilatory actions of 
Hcy (Kennedy et al. 2006). Supplementation with B6, B 12, and folate reduced plasma Hcy in 
elderly patients with heart failure and decreased mean arterial blood pressure and pulse rate. 
These results suggest that B vitamin supplementation may improve the vasodilatory capacity 
in patients with underlying disease (Andersson et al. 2005). 
d. Factors affecting homocysteine concentration 
Epidemiological data from the NHANES III showed that total Hcy was positively 
correlated with male sex, age, race-ethnicity (higher in non-Hispanic whites than Mexican 
Americans), serum creatinine, systolic blood pressure, BMI, hard-liquor consumption, and 
smoking, but inversely associated with vitamin/mineral supplement use, serum folate, 
intracellular folate, and serum vitamin B12 (Ganji and Kafai 2003). The Hordaland 
Homocysteine Study examined whether changes in lifestyle influence total Hcy over time in 
a population-based, prospective study conducted in 7,031 subjects from western Norway. 
Changes in plasma vitamin status and vitamin supplement use, quitting smoking, weight 
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changes, baseline history of CVD or hypertension, and cardiovascular events during follow-
up were significantly associated with changes in total Hcy (Nurk et al. 2004). In a 
multivariate analysis of lifestyle determinants of plasma total Hcy concentration in the 
Hordaland Homocysteine Study, sex, age, folate intake, smoking status, and coffee 
consumption emerged as the strongest determinants and were associated with a high median 
total Hcy concentration and a pronounced skewness toward high total Hcy values (Nygard et 
al. 199$). Alcohol consumption (30 ml ethanol/day) was associated with an odds ratio of 
2.79 for hyperhomocysteinemia in a population of 974 middle aged Japanese men (Sakuta 
and Suzuki 2005). 
In across-sectional study of Hispanic and non-Hispanic elders, high fruit and 
vegetable consumption was related to lower total Hcy and CRP concentrations (Gao et al. 
2004), suggesting that lower total Hcy is associated with particular nutrients, such as folate 
and fiber. Contrary to the popular belief that a vegetarian diet protects against CVD, a 
Taiwanese study (Su et al. 2006) showed that plasma total Hcy and soluble vascular adhesion 
molecule concentrations were significantly higher in healthy postmenopausal vegetarians, 
placing these vegans at an increased risk for atherosclerotic CVD. However, further 
multivariate analysis revealed that age and systolic blood pressure, but not vegetarianism per 
se, as determinants of common carotid artery intima media thickness (Su et al. 2006). 
Multivariate analysis of dietary and lifestyle factors revealed that intakes of monounsaturated 
fatty acids, fiber, calcium, magnesium, folate, and vitamins A, E, C, B 1, and B6 were 
positively associated with serum folate concentration in a population of healthy Greek adults 
(n=486) (Hatzis et al. 2006). Intake of betaine-rich foods such as wheat, spinach, shellfish, 
and sugar beets (Zeisel et al. 2003) possibly decreases plasma total Hcy. In the Framingham 
Offspring Study, higher intakes of dietary choline and betaine were related to lower total Hcy 
independent of other determinants, including folate and other B vitamins (Cho et al. 2006). In 
a cross-sectional study using data from NHANES (1999-2000), total Hcy concentration was 
significantly lower in those consuming fortified cereals (Song et al. 2005a), suggesting that 
the universal fortification of grains with folic acid effectively reduced total Hcy 
concentration. 
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Since the B vitamins riboflavin, B6, and B1~ are involved as coenzymes in the Hcy 
metabolic pathway, multivitamin supplementation effectively reduces Hcy. Multivitamin 
supplementation with physiological doses of B vitamins reduced total Hcy in healthy elderly 
women (Wolters et al. 2005). A single oral dose of betaine lowered plasma Hcy within two 
hours in healthy subjects (Schwab et al. 2006), as betaine donates its methyl group to Hcy to 
convert it back to methionine. Folic acid supplementation increases betaine concentrations 
(Melse-Boonstra et al. 2005) and thus indirectly reduces Hcy. Folic acid also reduces Hcy 
directly as evidenced by the decrease in Hcy concentration after the universal fortification of 
grains with folic acid. 
3. C-Reactive Protein and Cardiovascular Disease Risk 
C-reactive protein has received substantial attention in recent years as a promising 
biological predictor of atherosclerotic CVD. This stems in part from a recent shift in thinking 
about the pathogenesis of CVD, a disease once considered to be primarily a lipid storage 
disease. Inflammation is now widely accepted as a central etiologic factor in the development 
and progress of CVD (Ross 1999). Local inflammatory processes may trigger the occurrence 
of vascular events by mediating plaque instability. An evolving body of work suggests that 
even a small increase in CRP within the normal range is predictive of future vascular events 
in apparently healthy, asymptomatic individuals (Hackman and Anand 2003). Prospective 
data have shown that CRP is a stronger predictor of CVD than LDL-C. CRP is only 
minimally associated with LDL-C (Ridker et al. 2002) and cannot be predicted from total 
cholesterol concentration (Ridker 2003a). CRP adds to the predictive value of lipid 
parameters in determining the risk of first myocardial infarction (Ridker et al. 1998). To 
differentiate among patients at low, moderate, and high risk of future cardiovascular events, 
the corresponding CRP values are less than 1, 1-3, and greater than 3 mg/L, respectively 
(Ridker et al. 2003b). 
a. Epidemiologic evidence for C-reactive protein 
Epidemiological data from adults (N=4,900) in the NHANES III revealed that there 
was a significant and more robust relationship between concomitant elevations of CRP plus 
Hcy and a history of myocardial infarction, heart failure, and any CVD event compared to an 
elevation in only one of these biomarkers (Cummings et al. 2006). According to some 
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authorities, measuring CRP alone better predicts a myocardial infarction than measuring total 
cholesterol or HDL-C (Ridker et al. 1998). Results from 15,745 women enrolled in the 
women's Health Study revealed that CRP was a stronger predictor of future cardiovascular 
events than LDL-C (Ridker et al. 2002) . Similar results were noticed in the Physician' s 
Health Study where CRP and the total cholesterol/HDL-C ratio emerged as the strongest 
independent predictors of peripheral arterial disease (Ridker et al. 2001). 
Results from 6,051 men and women in Finland showed that both CRP and tumor 
necrosis factor-alpha (TNF-oc) were significant, independent predictors of coronary heart 
disease and CVD events and total mortality among men (Tuomisto et al. 2006). Findings 
from this study provided further support for the role of inflammation in the pathogenesis of 
CVD. However, contrary to the above findings, results from the Framingham study showed 
that elevated CRP concentration provided no further prognostic information beyond that of 
traditional risk factor assessment to predict major cardiovascular events (Wilson et al. 2005).. 
Similarly, in very elderly men (mean age=75 years) from the same study, CRP was not 
associated with CVD. Further, nonsteroidal anti-inflammatory drug use did not influence 
cytokine or CRP concentration in this population (Haider et al. 2004). In a prospective, 
nested, case-control analysis involving 97 cases of sudden cardiac death among apparently 
healthy men enrolled in the Physician's Health Study, CRP but not Hcy or lipid 
concentration, was significantly associated with risk of sudden cardiac death (Albert et al. 
2002). In the Rotterdam study, CRP was found to be positively associated with the severity 
of atherosclerosis (van der Meer et al. 2002), further lending evidence to the role of 
inflammation in atherosclerosis. 
b. Purported mechanisms for C-reactive protein 
As we now understand atherosclerosis to be an inflammatory process, much data are 
evolving to suggest that CRP promotes atherogenesis. CRP is detectable in the early stages of 
plaque formation and is thus believed to be an integral part of the atherogenic process, 
facilitating events from the initial recruitment of leukocytes to the arterial wall, to the 
eventual rupture of the plaque (Ridker et al. 2003b). The broad mechanisms underlying the 
effect of CRP on atherosclerotic CVD risk are elaborated upon below. 
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1) Endothelial dysfunction: The endothelium is a single cell protective 
lining for blood vessels, valves, and numerous body cavities. A balance between the relaxing 
and contracting factors secreted by the endothelium results in vascular homeostasis (Verma 
and Anderson 2002). Endothelial cell dysfunction, an early and central event in lesion 
formation, results in vasoconstriction, leukocyte adherence, platelet activation, mitogenesis, 
pro-oxidation, thrombosis, impaired coagulation, vascular inflammation, and atherosclerosis 
(Verma and Anderson 2002). Although traditionally thought to be a passive downstream 
marker in the inflammatory process, a growing body of evidence implicates CRP as a direct 
mediator of endothelial dysfunction. CRP induces the expression of adhesion molecules, 
such as intercellular adhesion molecule- 1, vascular cell adhesion molecule- 1, and E-selectin 
in human endothelial cells (Pasceri et al. 2000). Additionally, culturing human umbilical vein 
endothelial cells with CRP has revealed an increase in production of another adhesion 
molecule, chemokine monocyte chemoattractant protein- 1, further strengthening the role of 
CRP in the pathogenesis of vascular inflammation (Pasceri et al. 2001). CRP causes a 
marked and sustained increase in native LDL uptake by macrophages through increased 
secretion of endothelium-derived vasoactive factor endothelin-1 and the inflammatory 
cytokine IL-6 (Verma et al. 2002a). The number of circulating endothelial progenitor cells is 
positively associated with endothelial function and inversely associated with cardiovascular 
risk (Hill et al. 2003). When endothelial progenitor cells are cultured with CRP, there is 
inhibition of cell differentiation and survival, partly mediated through reduced endothelial 
nitric oxide synthase expression produced by endothelial progenitor cells (Verma et al. 
2004). 
A widely accepted definition .of endothelial dysfunction is a reduction in endothelial 
nitric oxide, which may result from reduced expression of endothelial nitric oxide synthase 
(Moncada and Higgs 2006). Nitric oxide is known for its vasodilatory and platelet inhibitory 
actions and was found to inhibit vascular smooth muscle proliferation (Moncada and Higgs 
2006). Less endothelial nitric oxide synthase activity reduces the bioavailability of nitric 
oxide, resulting in inhibition of vasodilatation, stimulation of LDL oxidation (oxLDL), 
smooth muscle proliferation, and monocyte adhesion (de Maat and Trion 2004). CRP causes 
a marked downregulation of endothelial nitric oxide synthase (Venugopal et al. 2002). This 
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occurs in part through posttranscriptional effects of endothelial nitric oxide synthase on 
mRNA stability (Verma et al. 2002b), thereby resulting in monocyte adhesion (Venugopal et 
al. 2002; Mineo et al. 2005). Numerous studies have shown that oxLDL plays a pivotal role 
in endothelial dysfunction. Li et al (2004) demonstrated that CRP increased human monocyte 
adhesion to endothelial cells and oxLDL uptake by these cells in vitro, both through 
increased expression of lectin-like oxLDL receptor-1. 
2) Monocyte recruitment: CRP seems to play a key role in monocyte 
recruitment, infiltration into the vessel wall, and finally formation of foam cells. Cell culture 
work in human endothelial cells showed that CRP upregulated the IL-8 gene in a time- and 
dose-dependent pattern and also enhanced monocyte adhesion to the endothelial cell layer 
(Wang et al. 2005). Inhibition of IL-8 significantly decreased (31 °Io) monocyte-endothelial 
cell adhesion induced by CRP (Devaraj et al. 2004). CRP promoted monocyte 
chemoattractant protein-1 mediated chemotaxis receptor-2 expression in human monocytes 
(Han et al. 2004). Monocytes trafficked to the site of an atherosclerotic lesion may take up 
excess lipid, transform into foam cells, and be incorporated into the atheroma itself. CRP is 
chemotactic for freshly isolated human blood monocytes and CRP deposition precedes the 
appearance of monocytes in early atherosclerotic lesions (Torzewski et al. 2000). Moreover, 
monocytes have a receptor for CRP, which appears to be important in binding CRP and 
monocytes being taken up by an atherosclerotic lesion (Torzewski et al. 2000). Additionally, 
elevated blood CRP concentration increases the expression of a dominant chemokine 
receptor in monocytes, CC chemokine receptor 2, at both the protein and transcript levels. 
This receptor in turn enhances chemotaxis mediated by monocyte chemoattractant protein-1 
up to two-fold (Han et al. 2004), thus playing a pivotal role in atherosclerotic plaque 
formation. 
3) Complement activation: Complement activation in early 
atherosclerotic lesions is in part mediated by CRP in the atherosclerotic intima and may be 
interpreted as evidence for CRP-mediated complement activation in the arterial wall 
(Torzewski et al. 1998). Human CRP and complement activation are key mediators of 
ischemic injury (Griselli et al. 1999). A very important property of CRP is its ability to bind 
to the complement to form complement-CRP complexes and activate the classical 
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complement cascade (Marvell et al. 2005; Wolbink et al. 1996). Elevated concentration of 
the CRP-complement complexes is noted in clinical samples, indicating that CRP may 
induce activation of the complement in vivo (Wolbink et al. 1996). Griselli et al. (1999) 
showed that there was a 40% increase in infarct size in rats injected with CRP, suggesting 
that CRP and complement activation are major mediators of ischemic myocardial injury. 
Complement activation by CRP may increase CRP binding in the developing plaque by 
exposing more CRP binding sites on complement-attached smooth muscle cells (Li et al. 
1994). 
4) Thrombosis: CRP has been recently suggested to directly 
contribute to CVD by inducing a prothrombotic state. CRP inhibits the activity of tissue 
plasminogen activator via generation of proinflammatory cytokines (IL-1 beta and TNF-a) 
and is thus a procoagulant having implications for atherothrombosis (Singh et al. 2005). CRP 
also increases the expression and activity of the main inhibitor of fibrinolysis, plasminogen 
activator inhibitor- 1, in human aortic endothelial cells (Blann et al. 2003), thus promoting 
atherothrombosis. Nakakuki et al. (2005) demonstrated that the Rho/Rho-kinase signaling 
pathway, a pathway integrally involved in the development of atherosclerosis and in signal 
cascades related to inflammation, is responsible for increased plasminogen activator 
inhibitor-1 expression in bovine aortic endothelial cells. Danenberg and coworkers (2003) 
observed that in human-CRP transgenic mice (mice carrying a fragment of human genomic 
DNA consisting of the CRP gene), 28 days after transluminal injury, 75% of the femoral 
arteries were occluded compared to 17% in the wild type. Thus, CRP is not merely a marker 
of atherosclerosis, but also a mediator, as it contributes to underlying lesion formation, 
plaque rupture, and coronary thrombosis (verma and Yeh 2003). 
c. Factors affecting C-reactive protein concentration 
With both high and low levels of inflammation, CRP concentrations vary 
dramatically with diet, lifestyle, genetics, and disease state. In Spanish women, multiple 
regression analysis revealed that body mass index (BMI), triglycerides, and fasting glucose 
were independent predictors of CRP in women and together explained 42% of its variance. In 
Spanish men, CRP was independently and positively associated with waist circumference, 
smoking, diastolic blood pressure, uric acid, and triglycerides, and negatively associated with 
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HDL-C (r= -0.51) (Garcia-Lorda et al. 2006). Hoekstra et al. (2005) reported similar 
associations with BMI, serum insulin, and CRP. However, these relationships weakened in 
overweight women and lost significance, suggesting that the role of CRP in metabolic 
syndrome is modified by the amount of body fat. Excess body weight and body composition 
have strong effects on CRP concentrations. Measures of both total (fat mass, BMI) and 
abdominal adiposity (waist circumference, waist-to-hip ratio) were highly correlated with 
CRP in a population of 641 men and 597 women. In women, fat mass explained 18.2% of the 
variability in CRP, whereas waist-to-hip ratio explained 6.2°Io of the variability (Thorand et 
al. 2006). Physical activity is also associated with reduced CRP in older adults (Colbert et al. 
2004), although this inverse relation may be partly mediated through body weight and 
adiposity. 
In addition, CRP is affected by dietary intake, especially dietary fiber and whole 
grains. An inverse association between dietary fiber intake and serum CRP concentration was 
noted in 524 subjects (Ma et al. 2006). Consuming a carbohydrate restricted diet leads to a 
subsequent decrease in CRP (-8.1 °Io) but not in IL-6 in overweight/obese men who are 
otherwise healthy (Wood et al. 2006). Conversely, intake of whole grains and dietary fiber 
decreased CRP in 902 diabetic women in the Nurse's Health Study (Qi et al. 2006). Recent 
work by Desroches et al. (2006) showed that both a loes-fat diet and ahigh-monounsaturated 
fatty acid diet did not affect plasma CRP concentrations. Additionally, a decrease in dietary 
fat without a concurrent change in body weight does not affect CRP concentration in 
overweight healthy subjects (Koren et al. 2006), demonstrating that body weight and 
adiposity are stronger determinants of CRP concentration than diet alone. Dietary 
supplementation with polyunsaturated fatty acid had no effect on serum concentration of 
CRP in healthy subjects (Madsen et al. 2003). On the other hand, consumption of omega-3 
fatty acids decreased CRP and IL-6 concentrations in the general population (Zampelas et al. 
2005). An intake of dietary flavonoids (Song et al. 2005b) or green tea (Sung et al. 2005), 
each of which have antioxidant properties, does not have any effect on CRP or II.-6 
concentration. However, an Italian study reported that dietary total antioxidant capacity is 
inversely related to CRP concentration, especially in subjects with hypertension (Brighenti et 
al. 2005). In a survey of older adults, fruit and vegetable intake was inversely associated with 
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CRP concentration (Gao et al. 2004), which could potentially be due to the fiber content 
rather than the antioxidant content. Analysis of data from 891 participants from the 
population-based Framingham Heart Study cohort showed that low circulating pyridoxal 5'-
phosphate (PLP), the active form of vitamin B6, was associated with higher CRP 
independently of total Hcy. These results may reflect utilization of vitamin B6 during an 
underlying inflammatory process and may represent a possible mechanism to explain the 
decreased vitamin B6 concentration observed in those with CVD (Friso et al. 2001). 
In summary, although CRP is a strong predictor of CVD, the utility of CRP alone as a 
tool in global risk assessment has some important limitations. These include the poor 
specificity of CRP in the setting of coexisting inflammatory states (e.g., rheumatoid arthritis, 
chronic pulmonary disease, and infections) and relatively fewer data from ethnic groups other 
than Caucasians (Hackmand and Anand 2003). However, when CRP is combined with 
traditional risk factors, it adds to the predictive value of CVD risk assessment. 
E. RISK FACTORS FOR OSTEOPOROSIS 
1. Assessment of Bone Mineral Density 
Bone densitometry is the single best predictor of osteoporotic fracture risk and is used 
for assessing therapeutic interventions. Because of its predictive power, densitometric 
assessment is by far the most important information to obtain about fracture risk. Other 
independent predictors of fracture are readily known, such as age, history of previous 
fracture, and low body weight. Together, the risk profile of an individual can be accurately 
determined as long as the BMD is known (Miller et al. 1999). Several techniques are 
available for quantitative measurement of BMD (Table 2). The three most widely used 
techniques in a research setting are dual energy x-ray absorptiometry (DXA), quantitative 
computed tomography, and calcaneal ultrasonography. Among these, DXA is the most 
widely used technique and is considered the gold standard for measuring BMD. DXA is 
noninvasive, rapid, accurate, and safe. Although DXA can measure BMD at any skeletal site, 
the standard sites are the lumbar spine, the proximal femur, and the distal forearm. The high 
level of precision and low level of radiation exposure for this technique allows not only 
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Other techniques for measuring BMD have been developed. Quantitative computed 
tomography (QCT) measures lumbar spine and more recently has been adapted to measure 
peripheral sites as well (peripheral quantitative computed tomography; pQCT). The potential 
advantage of quantitative computed tomography over DXA is its ability to measure true 
volumetric density (grams/cm~) compared with DXA, which provides an areal density 
(grams/cm2). Moreover, quantitative computed tomography measures trabecular bone of the 
lumbar spine exclusively, devoid of the cortical envelope (Miller et al. 1999). This is of 
extreme importance because trabecular bone, due to its higher rate of turnover, is expected to 
show metabolic changes earlier (Brunader and Shelton 2002) than cortical bone. Trabecular 
bone is highly vascularized and provides the scaffolding for the ends of long bones. It is also 
responsible for hematopoiesis and mineral homeostasis and is the type of bone primarily lost 
with menopause (Nilas and Christiansen 1988). However, quantitative computed 
tomography, is expensive, not widely available, and exposes individuals to higher radiation 
levels. Fracture prediction by quantitative computed tomography is as good as but no better 
than that with DXA (Miller et al. 1999). 
Peripheral quantitative computed tomography is a noninvasive method (Grampp et al. 
1995) and provides accurate (Ebbesen et al. 1997) and precise (Sievanen et al. 1998) 
volumetric BMD, bone size, cortical geometry (Rauch et al. 1999), and apparent trabecular 
structure and connectivity (Takagi et al. 1995). High resolution pQCT measurements allow 
visualization of the trabecular bone microstructure. Using high resolution pQCT, 
osteoporotic changes are apparent on images of both the radius and tibia and structural 
parameters, such as trabecular number and separation, can be measured (Gluer et al. 1997). 
This is of importance, because in osteoporotic females, trabecular number is reduced, while 
in osteoporotic males, trabecular thickness is reduced (Mullender et al. 2005). For planar 
measurements like DXA, changes in density are substantially obscured by changes in bone 
size. Peripheral quantitative computed tomography measurements offer better methodology 
in such cases. Peripheral quantitative computed tomography also provides complete 
information on the distribution of bone mineral within the computed tomography slice image, 
and hence makes it possible to calculate biomechanically relevant parameters describing 
bone strength. Moreover, because of the distance from radiation sensitive organs, the 
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effective radiation exposure for pQCT measurements is very small (Gluer et al. 1997). 
Determination of BMD alone explains about 60-80°Io of the variation in bone strength 
but provides no information on bone architecture. Bone ultrasonography measures the speed 
of sound as well as broadband ultrasonic attenuation of the site being measured. Ultrasonic 
attenuation is thought to be related to bone architecture and ultrasound speed to material bone 
properties such as density, although these theories are not universally accepted. The most 
common site of measurement is the calcaneus. However, n.o cut-off values for diagnosis of 
osteoporosis using ultrasound have been developed and the World Health Organization 
criteria for defining bone density are largely based on DXA (Brunader and Shelton 2002). 
2. Established Risk Factors for Osteoporosis 
Osteoporosis is a devastating disorder with significant physical, psychosocial, and 
financial consequences. The risks for osteoporosis, as reflected by low bone density, and the 
risks for fracture overlap but are not identical (National Institutes of Health, NIH Consensus 
Statement 2000). The established risk factors for osteoporosis are variables associated with 
osteoporosis and can be categorized as primary and secondary risk factors. Primary risk 
factors include aging, female gender, low peak adult bone mass, Caucasian or Asian race, 
thin and/or small frame, estrogen deficiency (menopause or ammenorhea), family history of 
osteoporosis, immobilization, and use of certain medications (corticosteroids and 
anticonvulsants). Secondary risk factors include cigarette smoking, excessive use of alcohol, 
lack of physical activity, dietary deficiencies of protein and vitamin K, dietary excesses of 
sodium, caffeine and protein, inadequate lifetime calcium intake, and poor vitamin D status. 
Heavy coffee consumption or caffeine intake has been thought to be a risk factor for low 
bone density, fracture risk, and osteoporosis by some researchers (Kiel et al. 1990) while 
other studies have contradicted this (Sakamoto et al. 2001; Lloyd et al. 1997). Cummings et 
al. (1995) assessed potential risk factors for hip fracture in 9,516 white women. They 
reported that risk was higher among women who had previous fractures of any type after the 
age of 50, were tall at the age of 25, rated their own health as fair or poor, had previous 
hyperthyroidism, had been treated with long-acting benzodiazepines or anticonvulsant drugs 
ingested high amounts of caffeine, or spent four hours a day or less on their feet. 
Additionally, low calcaneal bone density was also an independent risk factor. The incidence 
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of hip fracture was 1.1 per 1000 woman-years among women with normal calcaneal bone 
density who had two or fewer risk factors, whereas this incidence increased to 27 per 1000 
woman-years among those with bone density in the lowest tertile who had five or more risk 
factors. Adequate calcium and vitamin D intake are crucial to develop optimal peak bone 
density and to preserve bone throughout life. Supplementation of these two components in 
bioavailable forms may be necessary in individuals who do not achieve recommended intake 
from dietary sources (National Institutes of Health, NIH Consensus Statement 2000). 
Calcium intake has been shown to reduce the risk of fracture in several prospective cohort 
studies (Feskanich et al. 1997; Cumming et al. 1997). However, ameta-analysis of six 
prospectively studied cohorts did not show an increase in fracture risk with low calcium 
intake (Kanis et al. 2005). Regular exercise, especially resistance and high-impact activities, 
also contribute to development of high peak bone density and may reduce the risk of falls in 
older individuals (National Institutes of Health, NIH Consensus Statement 2000). Lifetime 
habitual physical activity prevents bone loss at weight bearing sites of the skeleton 
(Greendale et al. 199 ; Korpelainen et al. 2006) because the skeleton responds to mechanical 
stress with a stimulation of osteoblast activity resulting in increased BMD (Korpelainen et al. 
2006). In addition to the above risk factors, genetics account for a significant proportion of 
the variation in BMD. In a recent study in 570 Amish women, genetics accounted for 58-
88% of the total variation in BMD in pre-menopausal women compared to 37-54°Io of the 
total variation in postmenopausal women (Brown et al. 2005). 
3. Homocysteine and Bone 
Osteoporosis is a multifactorial disease. In addition to the traditional risk factors for 
osteoporosis, Hcy has recently emerged as a novel risk factor. It has been hypothesized that 
the metabolism of Hcy is involved in osteoporosis. Homocystinuria, arare autosomal 
recessive disease characterized by markedly elevated concentration of plasma Hcy, has 
several clinical manifestations involving the eyes, the vasculature, and the central nervous 
system. The presence of homocystinuria is associated with the early onset of osteoporosis. 
The underlying pathophysiological mechanism for the occurrence of early osteoporosis in 
patients who have homocystinuria is not completely understood. However, in vivo and in 
vitro studies support the concept that an Hcy-associated disturbance in collagen cross-linking 
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in bone is involved. The increased prevalence of osteoporosis among people with 
homocystinuria suggests that a high serum Hcy concentration may weaken bone (van Meurs 
et al. 2004). 
a. Epidemiologic evidence for homocysteine and bone density/fracture 
risk 
Numerous studies have demonstrated a link between increased plasma Hcy 
concentration and the risk of osteoporotic fracture. Results from 825 men and 1,174 women 
aged 59-91 years in the Framingham Study showed that subjects in the highest quartile of 
total Hcy had a greater risk of hip fracture than those in the lowest quartile (McLean et al. 
2004). In addition, this risk was almost four times as high for men and 1.9 times as high for 
women. In 2,268 men aged 47-50 years and 3,070 women aged 71-75 years from the 
Hordaland Homocysteine Study cohort, plasma total Hcy was inversely related (P<0.001) to 
BMD among middle-aged and elderly women but not among men. This association remained 
significant after additional adjustments for plasma folate or intake of calcium and vitamin D. 
The multiple adjusted odds ratio for low BMD was 1.96 in those with high (>15 µmoUL) 
total Hcy compared with low (<9 µmol/L) total Hcy, but this was not significant for men. 
Interestingly, there were no associations between plasma folate, vitamin B 12, or MTHFR 
polymorphisms and BMD (Gjesdal et al. 2006). 
Two large prospective studies examined the relation between Hcy and risk of 
osteoporotic fracture in a population setting. van Meurs et al. (2004) studied 2,406 subjects 
from the Rotterdam Study and the Longitudinal Aging Study Amsterdam. The relative risk of 
fracture after adjusting for other variables was 1.4 for each SD increase in Hcy concentration. 
Subjects with a Hcy concentration above the cut-off value had atwo-fold increase in fracture 
risk compared to subjects with lower values. These risk estimates were similar between men 
and women. Reporting similar results, Sato and coworkers (2005) examined the association 
between plasma Hcy and the risk of hip fracture in 433 stroke patients. Age-adjusted 
incidence rates per 1000 person-years for hip fracture increased linearly from 2.9 in the 
lowest quartile to 27.9 in the highest quartile of Hcy concentration. Multivariable-adjusted 
Cox proportional hazards regression analysis for quartiles of total Hcy showed that for each 
SD increase in total Hcy concentration, the risk of hip fracture increased by 35°Io. 
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A Turkish study in 79 postmenopausal women stated that Hcy concentration was 
significantly higher in osteoporotic postmenopausal women compared to their healthy 
counterparts (Yilmaz et al. 2006). Sato et al. (2005a) studied the risk of hip fracture in elderly 
women with Parkinson's disease. Results from this study revealed that the risk of hip fracture 
in women with Parkinson's disease was greatest in the highest quartile of Hcy and this risk 
was 2.4 times higher than the risk in the lowest quartile. It is known that L-3,4-
dihydroxyphenylalanine that is used to treat Parkinson's disease, increases Hcy concentration 
(O'Suilleabhain et al. 2004); the increased risk of fracture might have been related to L-3,4-
dihydroxyphenylalanine use. Additionally, these patients exhibit altered calcium and vitamin 
D metabolism (Sato et al. 2005b) which might have possibly increased fracture rate. 
b. Purported mechanism for homocysteine in osteoporosis 
McKusick in the mid 1960's first hypothesized that a disturbance in the metabolism 
of mucopolysaccharides could result in altered collagen synthesis due to a deficiency of 
sulfur donors (McKusick 1966). McKusick also speculated that Hcy interferes with collagen 
cross-linking, impairing bone integrity. One of the first studies to examine the McKusick 
hypothesis was published by Lubec et al. (1996) who studied collagen type I and type III 
synthesis in 10 homocystinuric patients. Although collagen type I and type III synthesis was 
not different between patients and controls, collagen type Icross-links expressed by serum 
carboxyterminal telopeptide of collagen type I were significantly lower in the patient group 
compared to the control group. This significant reduction of cross-links in the 
homocystinuric group did not correlate with serum Hcy or homocysteic acid concentrations. 
These results partly support the McKusick hypothesis since disturbed collagen cross-linking 
occurs in homocystinuria, but the bone manifestations are not necessarily due to deficient 
collagen synthesis. In apparent contrast to these results, Bode et al. (2000) found a positive 
correlation between serum carboxyterminal telopeptide of collagen type I and Hcy 
concentration in 109 patients undergoing a coronary bypass graft. Because of the low number 
of subjects in both studies and lack of further studies on carboxyterminal telopeptide of 
collagen type I concentration in homocystinuric patients, the results of these studies require 
corroboration. 
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In developing chicks supplemented with O.balo dl-Hcy for the first eight weeks, 
hyperhomocysteinemic animals grew faster and had longer and wider tibiae at the end of 
eight weeks, despite normal indices of bone formation. Additionally, the bone carbonate to 
phosphate ratio was significantly decreased, demonstrating qualitative alterations in the 
cortical bone mineral composition (Masse et al. 2003). Herrmann et al. (2005) recently 
showed that high Hcy stimulates osteoclast activity in vitro. Interestingly, this activity did not 
increase in the presence of equimolar concentrations of the related thiols cysteine and 
glutathione, implicating Hcy in bone resorption. 
To understand the mechanism by which hyperhomocysteinemia affects bone, 
Sakamoto et al. (2005) recently investigated the effects of Hcy on expression of osteocalcin 
and osteopontin, two non-collagenous extracellular bone proteins, in MC3T3-E 1 
preosteoblastic cells. Osteocalcin decreased by approximately 61 % in cells treated with 500 
µmol/L Hcy, while osteopontin increased from 134% to 209% of the control level. Hcy 
decreased osteocalcin mRNA but increased osteopontin mRNA without affecting cell 
viability (Sakamoto et al. 2005). On the contrary, a recent study by Herrmann et al. (2005a) 
in peri- and postmenopausal women showed that circulating osteocalcin was not associated 
with Hcy. Additionally, partial correlation analysis controlling for several variables did not 
reveal significant relation between Hcy and BMD of the hip (P=0.23) or lumbar spine 
(P=0.07). However, weak but significant associations between Hcy and urinary 
deoxypyridinoline cross-links, a marker of bone resorption (r=0.19, P=0.022), and serum 
calcium (r=0.17, P=0.045) were observed, suggesting a mechanistic link between Hcy and 
bone metabolism (Herrmann et al. 2005a). 
Cell culture work in primary human bone marrow stromal cells and a human bone 
marrow stromal cell line showed that Hcy induced apoptosis via the reactive oxygen species-
mediated mitochondrial pathway and nuclear factor-kappaB activation in human bone 
marrow stromal cells. Hence, Hcy may contribute to the development of osteoporosis by 
reducing bone formation. Hence, antioxidants may play a role in preventing bone loss in 
individuals with hyperhomocysteinemia (Kim et al. 2006). Osteoprotegerin is a member of 
the tumor necrosis factor superfamily and is involved in the regulation of bone metabolism 
and calcification of vascular tissue. A recent study by vik et al. (2006) in 58 patients (40-60 
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years) with verified myocardial infarction and age- and sex- matched case controls showed 
that serum osteoprotegerin concentration was similar in cases and controls (P=0.92). 
However, there was a significant correlation between osteoprotegerin and Hcy in patients 
(r=0.30, P=0.02) and controls (r=0.35, P=0.007), suggesting a mechanistic link between bone 
and vascular tissue. 
c. Factors affecting the relationship between homocysteine and bone 
1) Methylenetetrahydrofolate reductase polymorphisms: 
Polymorphism in the gene encoding MTHFR is probably the most extensively studied of the 
genetic factors influencing hyperhomocysteinemia. Miyao et al. (2000) have noted that this 
polymorphism is associated with reduced BMD in postmenopausal Japanese women with the 
TT genotype. Data from the Danish Osteoporosis Prevention Study revealed similar 
associations in early postmenopausal women. Subjects with the TT genotype had 
significantly lower BMD at the hip and lumbar spine and atwo-fold higher fracture rate 
compared with their wild-type CC counterparts (Abrahamsen et al. 2003). In contrast, a study 
in early postmenopausal Scottish women showed that there was no significant association 
between femoral neck and lumbar spine BMD with the MTHFR genotype. However, dietary 
riboflavin, a vitamin upon which MTHrlZ is dependent, correlated positively with lumbar 
spine and femoral neck BMD in homozygotes for the MTHr'K `T' allele, indicting the 
possibility that riboflavin intake and MTHrK genotype might interact to regulate BMD 
(MacDonald et al. 2004). 
Villadsen et al. (2005) more recently demonstrated that the TT genotype is 
significantly more common (14.3%) in Danish women with vertebral fractures than normal 
controls (8%). However, these women did not have a significantly lower BMD than their 
counterparts. Logistic regression analysis showed that vertebral fracture was associated with 
BMD, but only weakly (P=0.06) with MTHFR genotypes. In another study with 689 elderly 
Danish twins, the risk of fracture was 1.5 times higher in the TT genotype versus the CT 
group, and 1.5 times higher in the CT group versus the CC group. Interestingly, Hcy 
provided no significant contribution to fracture ri sk (Bathum et al. 2004). In a similar study 
in Danish postmenopausal women, logistic regression analyses showed that individuals 
homozygotic for the C-allele had a higher risk of lower forearm fracture (odds ratio=3.93, 
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P=0.02), hip fracture (odds ratio=6.99, P=0.02) and combined fractures (odds ratio=4.33, 
P=0.002) compared with those homozygotic for the T-allele (Jorgensen et al. 2002). 
2) Folate: The inconsistencies in results from studies examining the 
MTHFR genotype could arise due to a possible gene-nutrient interaction. The MTHFR and 
associated enzymes together with a number of the B vitamins are required for the 
remethylation of Hcy to methionine (Cashman 2005). Folate, an important co-enzyme in the 
Hcy metabolic pathway, is emerging as a predictive factor for BMD. McLean and coworkers 
(2004a) determined whether folate status might modify an association between the C677T 
polymorphism and bone, possibly by influencing Hcy concentrations. Researchers found that 
compared with participants with at least one wild type allele (CC+CT group), the TT group 
had lower mean broadband ultrasound attenuation (P=0.06) and Ward's triangle BMD 
(P=0.08) within the lower plasma folate (< 4 ng/ml) group, but significantly higher hip BMD 
(P<0.05) within the higher plasma folate (> 4 ng/ml) group. The authors chose 4 ng/ml as a 
cut-off because this was considered below the normal level of 5 ng/ml and was close to the 
median value for the population. The mechanism underlying this association with bone is still 
unclear, but researchers hypothesize that the effects may be partially mediated by Hcy. 
However, it must be noted that determination of plasma folate in this study was assessed at 
least four years before bone phenotype measurements were made. Plasma folate 
concentration reflects recent dietary intake of folate rather than long term folate status. 
Moreover, the government mandated a nationwide fortification of enriched grains with folic 
acid, which was introduced during this four year period. 
Cagnacci et al. (2003) demonstrated that serum folate but not Hcy or vitamin S12 was 
independently related to lumbar spine BMD in 161 postmenopausal women. Similarly, an 
Italian study assessed the risk of osteoporotic fractures in 978 elderly persons using data from 
the Conselice Study of Brain Aging. Following adjustment for serum folate and vitamin B12, 
for each 1 SD increase in plasma Hcy, the odds ratio for fracture ri sk decreased from 1.4 to 
1.2. Multivariate-adjusted risk of fracture doubled for persons in the lowest serum folate 
quartile compared to the higher quartiles. No independent association with BMD was found 
for vitamin B12 (Ravaglia et al. 2005). Conversely, recent work in healthy non-osteoporotic 
women showed that short-term folate supplementation (1 mg/d or 5 mg/d) for eight weeks 
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did not affect biochemical bone markers (Herrmann et al. 2006). An Iranian study found that 
BMD of femoral neck and lumbar spine were negatively correlated with Hcy but not 
MTHFR polymorphism. However, this association of Hcy with bone weakened when 
adjusted for circulating folate and vitamin B 12 (Golbahar et al. 2004). Results of these studies 
are somewhat limited in that serum folate, an indicator of short-term folate status, rather than 
intracellular folate, along-term indicator of folate status, was studied. 
3) Vitamin B 12: Vitamin B 12, an important co-enzyme in Hcy 
metabolism, has also been implicated for its role in low BMD. Morris et al. (2005) studied 
the relation among intracellular folate, vitamin B 12, Hcy, and BMD in participants of 
NHANES III. Although serum vitamin B 1 ~ was related to BMD in adose-response fashion, 
serum or intracellular folate was not associated with osteoporosis and BMD. Subjects with 
serum Hcy > 20~,mol/L had significantly lower BMD than those with serum values 
20~,mol/L. Similar results were published by Dhonukshe-Rotten et al. (2003) in a population 
of frail, elderly Dutch women. Women with osteoporosis had a significantly lower serum 
concentration of vitamin B 12 than women with osteopenia or normal BMD. A more recent 
randomized double-blind placebo-controlled trial by Sato and co-workers (2005c) in 628 
patients with residual hemiplegia at least one year following their first ischemic stroke 
showed that a Hcy lowering therapy with 5 mg folate and 1500 ~,g vitamin B1~ reduced the 
hip fracture rate. The number of hip fractures per 1000 patient-years was 10 and 43, 
respectively, for the treatment and placebo groups. However, it is not clear from this study if 
improved folate and vitamin B 12 status or decreased Hcy concentrations caused the decrease 
in fracture risk. 
Results from data collected on adult participants in the Framingham Offspring 
Osteoporosis Study demonstrated that men and women with low vitamin B 12 concentrations 
(<200 pg/ml; < 148 pmol/L) had lower than average BMD compared with those above this 
cut-off (Tucker et al. 2005). A prospective study in 615 men and 652 women in the 
Longitudinal Aging Study Amsterdam showed that low vitamin B 12 status, high Hcy 
concentration, or both was associated with a higher risk for fracture in men (relative risk=3.8) 
and in women (relative risk=2.8). This study supports the McKusick hypothesis that women 
with elevated Hcy also had high deoxypyridinoline /creatinine, suggesting that high Hcy 
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results in an altered bone matrix by interfering with the formation of collagen cross-links 
(Dhonukshe-Rutten et al 2005). 
In one of the first studies relating vitamin B12 to bone, Carmel et al. (1988) suggested 
that osteoblast activity depends on vitamin BIZ and that bone metabolism is affected by 
vitamin B12 deficiency. In several studies, vitamin B 12 has been associated with osteoblast 
activity and bone formation (van Dommelen et al. 1964; Carmel et al. 1988; Kim et al. 1996). 
Anemia due to vitamin B12 deficiency is associated with reduced BMD of the lumbar spine 
(Eastell et al. 1992) and with vertebral fractures (Goerss et al. 1992). Whether this 
relationship is independent of Hcy is unclear. Stone and colleagues (2004) examined the 
relationship between low serum vitamin B12 and bone loss in 83 elderly women who 
participated in the Study of Osteoporotic Fractures. They reported that after adjusting for age,. 
weight, and clinic site, women with vitamin B12 <_280 pg/ml experienced an annual change of 
-1.6°Io in total hip BMD, compared with -0.2°Io in women with concentrations >280 pg/ml 
(P=0.003). Serum vitamin B12 was not associated with rate of change in calcaneal BMD in 
this cohort. 
4. C-Reactive Protein and Eone 
a. Epidemiologic evidence for immune imodulators and bone 
Although a few studies have demonstrated an association between CRP concentration 
and BMD or biochemical markers of bone turnover in several immune (Bakri Hassan et al. 
1998) and inflammatory diseases (Haugeberg et al. 2006; Punzi et al. 2005), there is a 
paucity of information examining this relation in non-inflammatory conditions and in 
osteoporotic or postmenopausal subjects. In a multivariate linear regression model, mean 
CRP was found to be independently associated (P<0.001) with change in hand BMD during 
follow-up of patients with early undifferentiated rheumatoid arthritis (Haugeberg et al. 2006). 
Similarly, CRP concentration is higher in erosive osteoarthritis than in non-erosive 
osteoarthritis patients (Punzi et al. 2005). Osteoporotic patients with ankylosing spondylitis 
were also found to have significantly higher CRP (Lange et al. 2005). In one of the first 
studies relating CRP concentration to BMD in pre- and postmenopausal women, Koh and 
coworkers (2005) demonstrated that higher circulating CRP was associated with lower BMD. 
Compared with normal subjects, serum CRP was higher in osteopenic and osteoporotic 
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subjects (P<0.001), after adjustment for age, BMI, and menopausal status. These studies 
suggest a link between systemic inflammation as reflected by CRP and BMD. 
b. Purported mechanisms for C-reactive protein in osteoporosis 
1) IL-6 and bone: A plethora of information suggests that the immune 
system modifies bone resorption and probably bone formation through interactions involving 
T and B lymphocytes, dendritic cells, cytokines, and cell to cell interactions. The immune 
system plays a critical role in the bone remodeling cycle and this interaction between 
osteoclasts and osteoblasts is mediated primarily through the receptor activator of nuclear 
factor kappaB (RANK)/RANK ligand (RANKL)/osteoprotegerin system Various cytokines, 
including IL-6, IL- l , and TNF-a regulate both the immune response and the bone remodeling 
process (Clowes et al. 2005). 
Since CRP is produced in the liver in response to IL-6, the relation between IL-6 and 
bone is important to consider. IL-6 is a key cytokine for osteoclastogenesis (Carlsten 2005). 
Ohsaki et al. (1992) demonstrated that giant tumor cells, which have many features of 
osteoclasts, synthesize and secrete IL-6, suggesting that IL-6 plays an autocrine/paracrine 
role in bone resorption. Adebanjo and coworkers (1998) showed that IL-6 receptor 
expression was present in single osteoclasts. Additionally, IL-6 reversed the inhibition of 
osteoclastic bone resorption induced by high extracellular Cat+ (Adebanjo et al. 1998). IL-6 
has been implicated as a facilitator of osteoclast precursor proliferation and a stimulator of 
bone resorption by mature osteoclasts (Pfeilschifter et al. 2002). In accordance with this, 
Tsangari and coworkers (2004) documented an increased expression of IL-6 mRNA in 
human trabecular bone of patients who had undergone a fragility fracture of the femoral 
neck, but not from those in the control group. These findings may be representative of the 
role IL-6 plays in the bone microenvironment, independent of circulating IL-6 concentration 
(Tsangari et al. 2004). de Hooge et al. (2005) demonstrated that IL-6 gene knockout male 
mice had lower BMD and developed more advanced osteoarthritis with aging. Recent work 
by O'Brien and colleagues (2005) showed that IL-6 gene expression in vivo did not change 
with an increase in parathyroid hormone and IL-6 was not required for the osteoclast 
formation and bone loss that accompanies continuous elevation of parathyroid hormone. On 
the contrary, work by Nakchbandi and others (2002) has shown that circulating concentration 
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of soluble IL-6 receptors correlate significantly (P<0.01) with rate of total femur bone loss in 
patients with hyperparathyroidism. In a study in Poland, postmenopausal women with type 1 
diabetes had significantly lower BMD at the femoral neck a.nd higher serum bioactive IL-6 
concentration compared with the control group. However, using multiple regression analysis, 
no association was found between IL-6 and BMD in these women (Rachon et al. 2003). 
2) Estrogen and IL-6: Menopause triggers changes in pro-
inflammatory cytokines. Changes in cytokine activity have been purported as a common 
underlying mechanism for various diseases. It is now well known that estrogen deficiency 
enhances the responsiveness of cells toward some of these cytokines by up-regulating 
cytokine receptor number and cofactors, thus amplifying the increase in cytokine response 
(Pfeilschifter et al. 2002). Because bone-regulating cytokines, such as IL- 1, TNF-a, and IL-6, 
synergize to stimulate their own and each other's synthesis, a small change in one cytokine in 
the bone microenvironment could dramatically alter the concentration of the others (Riggs 
2000) . 
Estrogen withdrawal is associated with an increased potential of human bone marrow 
cells to release bone-resorting cytokines, especially IL-6 (Bismar et al. 1995). The receptor 
for estrogen is known to suppress IL-6 gene expression through interaction with nuclear 
factor-kappaB in ahormone-dependent manner (Liu et al. 2005) and hence estrogen 
deficiency is associated with increased IL-6 concentration. Animal studies have shown that a 
loss of ovarian function up-regulates osteoclastogenesis in vivo in mice through an increase 
in II.-6 production in the microenvironment of the bone marrow (Jilka et al. 1992). In vitro 
evidence from cell culture work on murine bone marrow-derived stromal cell lines, normal 
human bone-derived cells, and nontransformed osteoblast cell lines from mice and rats have 
shown that 173-estradiol decreases IL-6 mRNA concentration. This suggests, for the first 
time, a mechanistic paradigm by which estrogens might exert at least part of their 
antiresorptive influence on the skeleton (Girasole et al. 1992). Work on bone marrow 
cultures showed that estrogen loss causes an up-regulation of IL-6 by bone marrow cells and 
a similar phenomenon can be elicited in vivo by withdrawal of 17(3-estradiol from primary 
cultures of bone cells (Passeri et al. 1993). Consistent with these observations, increased IL-6 
concentration was detected in bone marrow supernatant from ovariectomized rats compared 
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to sham operated mice (Miyaura et al. 1995) and in serum of postmenopausal compared with 
premenopausal women (Lakatos et al. 1997). On the contrary, in an in vivo mouse model, 
Vargas et al. (1996) did not find an increase in IL-6 production with estrogen withdrawal. 
Work in postmenopausal women revealed that there were no significant correlations between 
serum IL-6 concentration and menopausal status, serum estradiol concentration, or markers 
of bone turnover (McKane et al. 1994). Also, there were rao differences in IL-6 concentration 
in bone marrow aspirates of postmenopausal women receiving estrogen therapy or controls 
(Kassem et al. 1996). However, raloxifene, a selective estrogen receptor modulator, reduced 
bone loss and prevented vertebral fractures (Ettinger et al. 1999) by inhibiting IL-6 
production by 25-45% (P<0.001) in human trabecular osteoblasts (Viereck et al. 2003). In an 
ovariectomized rat model of menopause, a standardized soy extract produced a decrease in 
serum IL-6 and showed abone-sparing effect, which was partially attributed to the 
modulation of osteoclastogenesis induced by IL-6 (Gallo et al. 2005). 
F. HORMONE THERAPY TO REDUCE RISK OF CARDIOVASCULAR DISEASE AND 
OSTEOPOROSIS 
Hormone therapy for peri- and postmenopausal women prevents or decreases the 
discomfort associated with menopausal symptoms caused by diminished circulating estrogen. 
Hormone therapy is generally provided as a low dosage of one or more estrogens and 
typically combined with either progesterone or with its chemical analogue, progestin. The 
combination of estrogen and progesterone (combined hormone therapy) is usually prescribed 
for women with intact uteri. In women who have had a hysterectomy, an estrogen compound 
is usually given without any progesterone, a therapy referred to as unopposed estrogen 
therapy. 
The routes of estrogen administration include oral (pill), transdermal (patch), creams, 
gels, topical emulsions, and vaginal ring. Several oral and transdermal estrogen formulations 
are indicated for treatment of both vasomotor symptoms and symptoms of vulvar and vaginal 
atrophy (Stefanick 2005). In contrast, all combination hormone therapies (estrogen plus 
progesterone) are indicated for treating both vasomotor and vulvar/vaginal symptoms 
associated with menopause, and progestins (synthetic progesterone) are indicated for 
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managing estrogen-induced hyperplasia (Stefanick 2005). Dosage varies, with estrogen taken 
daily and progesterone or progestin taken for about 10 days to two weeks every month 
(sequentially combined hormone therapy). Alternatively, a constant dosage of both hormones 
may be taken daily and is referred to as continuous combined hormone therapy. 
Originally researchers believed that hormone therapy would protect against 
osteoporosis and CVD. However, several recent studies have provided conflicting data on the 
health effects of hormone therapy. For example, estradiol valerate and dionegest therapy for 
six months did not produce any change in plasma Hcy concentration (Pirimoglu et al. 2005), 
while oral doses of 17(3-estradiol effectively reduced lipoprotein (a), a risk factor for CVD 
(Hemelaar et al. 2003). Recent research indicates that while hormone therapy may help 
reduce bone loss and fractures, there are substantial risks for breast cancer, thromboembolism 
and CVD (Writing Group for the Women's Health Initiative [WHI] Investigators 2002). 
1. Cardiovascular Disease 
Several large clinical trials have documented the effects of hormone therapy on CVD. 
Results from the Framingham Heart Study in the mid 80's (1985) with postmenopausal 
women (N=1,234) revealed that estrogen users had over a 50% elevated risk of 
cardiovascular morbidity (P<0.01) and more than atwo-fold ri sk for cerebrovascular disease 
over an eight year period (Wilson et al. 1985). Interestingly, in the same year, the Nurses' 
Health Study with postmenopausal women (N=32,317) reported a 50°Io lower risk (adjusted 
relative risk=0.5; P=0.007) of coronary heart disease in estrogen users versus non users for 
an average 3.5 years of follow-up (Stampfer et al. 1985). The discrepancy between the results 
of these two highly respected prospective cohort studies was attributed to inclusion in the 
Framingham study of cardiovascular events other than myocardial infarction and coronary 
heart disease (e.g., angina pectoris, internuttent claudication, transient ischemic attack) and 
adjustment for HDL-C. At the time, this was considered possibly inappropriate because it 
was thought to be the most plausible mechanism of action for estrogen (Stefanick 2005). In 
1995, the Postmenopausal Estrogen/Progestin Intervention (PEPI) clinical trial demonstrated 
favorable lipoprotein changes in women assigned to conjugated equine estrogen with or 
without a progestin. These results reinforced the belief that estrogens reduce coronary heart 
disease risk, but also showed that the addition of cyclic or daily medroxyprogesterone, a 
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synthetic form of progesterone, reduced the beneficial effect of estrogen on HDL-C (The 
Writing Group for the PEPI Trial 1995). The Heart and Estrogen/Progestin Replacement 
study with postmenopausal women (N=2,763) who had established coronary disease reported 
that treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate (for an 
average of 4.1 years) did not reduce the overall rate of coronary heart disease events. Instead, 
hormone therapy increased the rate of thromboembolic events and gallbladder disease. 
In 2002, after a mean of 5.2 years of follow-up, the data and safety monitoring board 
of the WHI trial recommended stopping the estrogen plus progestin arm due to increased risk 
of breast cancer. Final analyses revealed a hazard ratio of 1.24 for coronary heart disease 
(Writing Group for the WHI Investigators 2002) in women in the estrogen plus progestin 
arm, which was most apparent and significant in the first year (hazard ratio=1.81). These 
findings were consistent with the effects of conjugated equine estrogen plus 
medroxyprogesterone acetate, observed in women with coronary heart disease in the Heart 
and Estrogen/Progestin Replacement trial. 
a. Homocysteine and hormone therapy 
Since Hcy is an independent risk factor for CVD, several studies have focused on 
reducing Hcy through hormone therapy to ameliorate the risk of heart disease in 
postmenopausal women. Work by Boers and colleagues (1983) in the early 80's revealed that 
fasting plasma Hcy concentration was significantly higher in postmenopausal women and in 
men than in women of reproductive age. Premenopausal women have a unique efficiency of 
methionine handling (Boers et al. 1983), and thereby are protected against increases in Hcy 
typically seen after menopause. Menopause is therefore a critical time for Hcy metabolism, 
suggesting that the increased ri sk of CVD observed in many women may be partially due to 
an increase in Hcy concentration (De Leo et al. 2004). Several but not all studies have 
documented the effectiveness of hormone therapy in reducing plasma Hcy. 
Findings from the NHANES III demonstrated the importance of estrogen in 
preventing increases in Hcy concentration. The mean serum total Hcy concentration of 
estrogen users greater than 55 years was significantly lower relative to non-estrogen users, 
independent of nutritional status or muscle mass (Morris et al. 2000). In a large prospective 
observational study in 438 Australian women, hormone therapy use was associated with 
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lower Hcy (Guthrie et al. 2005). In a prospective, randomized, placebo-controlled six month 
study in 107 healthy postmenopausal women, Hcy concentration decreased in all treatment 
arms: by 20% with unopposed conjugated equine estrogen, by 27% with conjugated equine 
estrogen plus medroxyprogesterone acetate, by 22% with conjugated equine estrogen plus 
nomegestrol acetate (a synthetic progestin) and by 34% with raloxifene. These decreases in 
Hcy were not statistically different between the groups (Gol et al. 2006) indicating a similar 
effect of estrogen, combined hormone therapy, and raloxifene. Similarly, Tutuncu et al. 
(2005) demonstrated no difference in the decrease in Hcy due to unopposed conjugated 
equine estrogen or conjugated equine estrogen combined with either of two doses of 
medroxyprogesterone acetate. Langer et al (2005) reported an Hcy lowering effect of 
hormone therapy in 608 women from the WHI cohort. Similarly, hormone therapy 
administered either as transdermal estrogen therapy or combined hormone therapy was 
effective in decreasing Hcy concentration in 120 postmenopausal women. These therapies 
decreased Hcy to premenopausal levels (Bednarek-Tupikowska et al. 2005). 
Oral administration of 17 ~-estradiol alone or combined with progesterone decreased 
Hcy concentration by 13 % and 10%, respectively, in a randomized, placebo-controlled, 
double-blind study in 25 postmenopausal women. In a multivariate analysis, the change in 
Hcy change was related to the change in albumin. The authors also observed that these 
changes were not accompanied by a change in the methionine-Hcy flux rate but hypothesized 
that a change in albumin metabolism plays an underlying mechanistic role in Hcy 
metabolism (Smolders et al. 2005). The initial concentration of Hcy may also be important. 
In a prospective, randomized study, sequential administration of a combination of estradiol 
and synthetic progesterone (norethisterone acetate), either orally or transdermally, did not 
cause a significant change in plasma Hcy in Finnish postmenopausal women with normal 
baseline Hcy concentration (Evio et al. 2000). In one of the earlier studies evaluating the 
effect of hormone therapy on Hcy concentration, van der Mooren and colleagues (1994) 
reported that in postmenopausal women with high Hcy, there was a 16.9% decrease in Hcy 
with a combination of continuous 17(3-estradiol and cyclic progesterone therapy. Hormone 
therapy did not cause a significant change in women with low Hcy. However, the sample size 
for this study was extremely small (N=21). The results of these studies suggest that hormone 
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therapy effectively lowers Hcy only in women with high Hcy and is of little use in women 
with normal concentration. 
Similar to the van der Mooren study (1994), administration of 173-estradiol plus 
progesterone either orally or transdermally for a period of six months in 49 healthy 
postmenopausal women caused significant reductions in Hcy (Chiantera et al. 2003). Using 
similar treatments, Mij atovic et al. (1998) evaluated Hcy concentrations in postmenopausal 
women treated with 173-estradiol and various doses of progesterone. The authors found a 
mean reduction of 13.5% in Hcy concentration without adose-dependent effect of 
progesterone. This decrease was reached by three months and sustained thereafter indicating 
a new stable metabolic steady state. However, results from the Postmenopausal 
Estrogen/Progestin Intervention trial have shown that administration of both conjugated 
equine estrogens and combined hormone therapy decreased Hcy only through 36 months, 
indicating a transient effect of hormone therapy (Barnabei et al. 1999). Similar results were 
also reported by van der Mooren and coworkers (1997) in 39 healthy postmenopausal 
women. The authors reported a reduction of 12.3% in plasma Hcy during the first six months 
of therapy in women with higher Hcy at baseline. However, these lower values returned to 
baseline during the second half year of treatment. Conversely, work by Hsu et al. (2005) 
revealed that the beneficial effects of hormone therapy were noticeable even after three years 
of treatment. It is thus difficult to conclude from these data whether the effects of hormone 
therapy are transient or have a sustained effect on Hcy. 
In apparent contrast to the above findings, D'Anna and colleagues (2005) found slight 
albeit not significant decreases in Hcy with six months of combined hormone therapy. 
Furthermore, Bruschi et al. (2004) found increases in plasma Hcy with oral or transdermal 
treatment with estradiol plus normegestrol acetate, a progesterone derivative, in 199 late 
postmenopausal women. In the oral treatment group, Hcy increased at 12 months by 22%; in 
the transdermal group, after a slight decrease at three months (1.5%), the increase at 12 
months was 13%. In the same year, Lacut et al. (2004) reported similar results in 196 
postmenopausal women who received either 173-estradiol orally or transdermally, both 
combined with a daily intake of progesterone, or placebo over a period of six months. 
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Additionally, the authors also reported decreases in serum vitamin B 12 with oral but not 
transdermal estrogen therapy. 
Altogether, it appears that hormone therapy either in the form of estrogen or 
combined with progesterone decreases the Hcy concentration in early postmenopausal 
women. The route of administration does not seem to have an effect on Hcy concentration. 
Nonetheless, it needs to be ascertained if these beneficial effects are transient or long lasting. 
However, hormone therapy in late postmenopausal women seems to have an adverse rather 
than beneficial effect by increasing Hcy. Plausible mechanisms underlying these increases 
should be further researched. 
b. C-reactive protein and hormone therapy 
In women, CRP concentration correlates with age and menopause (Woodward et al. 
2003), coincident with increased CVD risk. Numerous studies have demonstrated that 
estrogen and combined hormone therapy increase CRP in postmenopausal women. An Italian 
study indicated that either estrogen or estrogen-progestogen increased CRP, whereas 
estrogen decreased other inflammatory markers (Vitale et al. 2005). Results from the 
Estrogen Replacement in Atherosclerosis trial have shown that estrogen alone increased CRP 
by 40% at the end of 1 year of treatment (Lakoski et al. 2005). Data from a subset of 
postmenopausal women (n=221) from the Postmenopausal Estrogen/Progestin Intervention 
trial showed that all five treatment groups (3 different combined estrogen-progestin 
regimens, conjugated equine estrogen only, or placebo) resulted in increases at 12 months of 
estrone, sex hormone binding globulin, and CRP. Using an adjusted model to predict 12-
month CRP change, progestin plus estrogen, but not estrogen alone, increased CRP through 
an inflammatory mechanism (Reuben et al. 2006). Recent data from postmenopausal women 
(N=346) showed that the CRP concentration is increased in women using hormone therapy 
and is significantly higher in women with cardiovascular events compared to those without 
events (Vitale et al. 2005a). 
McKenzie and colleagues (2003) suggested that the typical increase in CRP 
concentration demonstrated with traditional hormone therapy is not evident with a Toes-dose 
continuous combined hormone therapy regimen in postmenopausal women with type 2 
diabetes. This study reported a significant decrease in IL-6 (P=0.015) but no significant 
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alteration in CRP (P=0.62) concentration. Results from an Italian study conducted with 
postmenopausal women (N=389) with increased CVD risk have noted a discrepancy between 
increased plasma CRP and reduced plasma concentration of all other markers of 
inflammation. These results suggest that the increased CRP with oral hormone therapy may 
be related to metabolic hepatic activation and not to an acute-phase response (Silvestri et al. 
2003). The route of administration also seems to impact CVD risk. For example, women 
using oral hormone therapy usually experience an increase in CRP (Hu et al. 2006; 
Bukowska et al. 2005; Eilertsen et al. 2005; Wakatsuki et al. 2004), while this increase is not 
typical in transdermal estrogen users (Sumino et al. 2005; Yilmazer et al. 2003; Kawano et 
al. 2003). Other studies have shown that transdermal hormone therapy does not have an 
effect on CRP (Lacut et al. 2003; Post et al. 2002; Vongpatanasin et al. 2003). In a subset of 
women (n=608) from the WHI Observational study, CRP was highest among women using 
unopposed conjugated equine estrogen. Among users of estrogen plus progestin, CRP 
concentration was higher in women with incident coronary events than healthy controls. 
Additionally, transdermal estrogen users had a lower CRP concentration (Langer et al. 2005). 
In a Turkish study, intranasal administration of 17(3-estradiol in 29 healthy hysterectomized, 
postmenopausal women did not change CRP concentration after six months of treatment 
(Kiran et al. 2004). It is thought that these adverse effects of oral hormone therapy may be 
due in part to first-pass hepatic processing (Bassuk et al. 2004). 
Contrary to the above mentioned findings, Kiran and Kiran (2006) illustrated that 
although conjugated equine estrogens plus medroxyprogesterone acetate caused a 29% 
increase in CRP concentration in postmenopausal women, these changes were not 
significant. In contrast, a prospective, randomized, placebo-controlled six month study in 
healthy postmenopausal women (N=107), CRP was not influenced by raloxifene, whereas 
conjugated equine estrogen or conjugated equine estrogen plus medroxyprogesterone acetate 
significantly increased CRP. On the other hand, another study showed that treatment with 
conjugated equine estrogen plus progesterone reduced serum CRP concentration (Gol et al. 
2006). 
Taken together, estrogen therapy is consistently associated with an elevation in CRP. 
On the other hand, progestin use appears to be beneficial as it seems to attenuate the effect of 
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oral estrogen on CRP. Transdermal and intranasal routes of administration do not seem to 
produce an elevation in CRP typically seen with oral use. Selective estrogen receptor 
modulators have various effects on CRP concentration. 
Despite these different effects of hormone therapy on CRP and Hcy, there is no 
substantive evidence that a change in these markers results in a modification of CVD risk. In 
fact, the WHI has demonstrated that hormone use increases CVD risk (Writing Group for the 
WHI Investigators 2002), particularly in late postmenopausal women. Further studies are 
required to specifically investigate whether treatments that increase or decrease these 
markers in fact modulate the risk of cardiovascular events in women. 
2.Osteoporosis 
Accelerated bone loss during the perimenopausal years has been attributed to 
estrogen deficiency due to ovarian failure. This bone loss contributes to a 20-30% loss in 
trabecular bone and a 5-10% loss in cortical bone (Riggs et al. 1998). Estrogen alone or in 
combination with progestin prevents bone loss at the spine and hip (Komulainen et al. 1999) 
and reduces hip fracture rates (Cawley et al. 1995). In elderly men from the Framingham 
study, the adjusted hazard ratio for a hip fracture was highest in men in the lowest quartile of 
estradiol concentration compared to men in the highest quartile (3.1 versus 0.9). Testosterone 
had no effect on hip fracture rates, thereby strengthening the idea that estrogen is the major 
player involved in osteoporosis. However, in an analysis in which men were grouped by both 
estradiol and testosterone concentrations, men with both low estradiol and low testosterone 
concentrations had the greatest risk for hip fracture (adjusted hazard ratio=6.5) (Amin et al. 
2006). 
In a large prospective cohort of Danish female nurses (N=7,082) aged 50-69 years, 
women who used estrogen alone had a 40°Io reduced fracture risk compared to a 56% 
reduction in women using combined therapy. The authors also found no protective effect of 
hormone therapy in women who discontinued hormone therapy use, irrespective of duration 
or recency of discontinuation (Hundrup et al. 2004). In the Framingham study, the relative 
risk of hip fracture for estrogen users at any time was 0.65 after adjustment for age and 
weight. This risk declined to 0.34 in those women who had taken estrogen in the last two 
years, supporting the hypothesis that use of estrogen protects against bone loss associated 
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with menopause (Kiel et al. 1987). Data from the WHI, in which women (with an intact 
uterus) were randomly assigned to estrogen plus progestin or a placebo, showed that 
hormone therapy increased total hip BMD and further reduced the risk of fracture at the hip, 
vertebrae, and wrist (Cauley et al. 2003). Similarly, in women who underwent hysterectomy, 
the estrogen alone arm also demonstrated a reduced risk of hip fracture by 30%-39% (The 
WHI Steering Committee 2003). 
Liu and Muse (2005) studied the efficacy of hormone therapy in preventing 
postmenopausal bone loss. In this two-year double-blind, placebo-controlled clinical trial, 
132 menopausal women were randomized into one of six treatment groups: micronized 
progesterone, medroxyprogesterone acetate, norethindrone (a progestin derived from 
testosterone), micronized estradiol, micronized estradiol plus medroxyprogesterone acetate or 
placebo. Micronized estradiol or micronized estradiol plus medroxyprogesterone acetate 
treatment increased lumbar spine BMD by 2%-4% over two years. Spinal BMD showed a 
tendency toward decline with micronized progesterone, medroxyprogesterone acetate, and 
placebo treatments. Change from baseline for the norethindrone arm was not found. At the 
femoral neck, BMD did not change significantly for any treatment group. The authors 
concluded that estrogen remains the primary bone active agent in hormone therapy and 
progestins have significantly less activity. 
Ina 10 year study of the effect of hormone therapy on lumbar spine BMD and distal 
forearm bone mineral content (BMC), Eiken and coworkers (1996) found that lumbar spine 
BMD was significantly higher (14.5%; P < 0.001) in women who received hormone therapy 
compared to the placebo. However, forearm BMC decreased by 0.7% over the 10 year period 
in the hormone therapy treatment group compared with a reduction of 17.6% (P<0.001) in 
untreated women. In a randomized, double-blind, placebo-controlled multicenter trial 
(Women's Health, Osteoporosis, Progestin, Estrogen), more than 85% of women on low dose 
conjugated estrogen plus medroxyprogesterone acetate did not experience continued hip 
BMD loss at 12 and 24 months, in contrast to 30.6% of women on placebo at 12 months and 
36.5°Io at 24 months (Lindsay et al. 2005). In an earlier study by the same group (Lindsay et 
al. 2002), data from healthy postmenopausal women (N=822) revealed that women using 
various doses of estrogen alone or combined estrogen plus progesterone had significant gains 
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(P<0.001) in spine and hip BMD and total body BMC. Results from bone biopsies obtained 
from postmenopausal women have shown that high doses of estradiol increase mineralization 
in total (cortical and trabecular) iliac bone by 6.9 ± 1.9% (8.6 ± 2.1 °Io in cortical bone, 6.5 ± 
2.1°Io in trabecular bone) (Boivin et al. 2005). An interesting study in postmenopausal women 
(N=81) showed that compared to placebo, medroxyprogesterone reduced the rate of loss in 
cortical areas of the skeleton, but not in the spine, which contains more trabecular bone. In 
contrast, estrogen reduced the rate of loss in both cortical and trabecular areas of the skeleton 
(Gallagher et al. 1991). 
To summarize, hormone therapy has demonstrated clinical fracture risk reduction. 
However, the increased risk of CVD and stroke, which were not counterbalanced by the 
small reduction in hip fracture rate in the WHI trial and the Heart and Estrogen/Progestin 
Replacement study suggest that hormone therapy could possibly exert a favorable 
risk benefit ratio. The use of hormone therapy is indicated for prevention of osteoporosis in 
postmenopausal women but not approved for sole use in the relief of vasomotor symptoms. 
Further research for safer alternatives to hormone therapy needs to continue. 
G. ISOFLAVONES AS AN ALTERNATIVE THERAPY TO REDUCE RISK OF CARDIOVASCULAR 
DISEASE AND OSTEOPOROSIS 
Isoflavones belong to a class of diphenol compounds called phytoestrogens and occur 
naturally in many plants. However, the Isoflavones (genistein, daidzein, and glycitein) 
derived from soy are relatively unique and are what we used in our study. Soy Isoflavones 
exist either as polar R-glucosides, such as genistin, daidzin, and glycitin, or in the free form 
as aglycones that include genistein, daidzein, and glycitein. In nature these soy Isoflavones, 
whether free or attached to a sugar moiety, occur in an approximate 5:4:1 ratio, respectively 
(Reinwald and Weaver 2006). Due to their structural similarity to 173-estradiol, soy 
Isoflavones have been widely studied for their estrogen-like effects and potential health 
benefits. 
1. Cardiovascular Disease 
In July 2002, results from the WHI trial drew much attention, when it provided strong 
evidence for an increased risk of CVD with the use of combined estrogen plus progestogen in 
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postmenopausal women. These unexpected results triggered an intense ongoing discussion 
about the role of hormone therapy in reducing CVD risk or bone loss associated with 
menopause. In a large population-based random sample of German women (N=8,380), aged 
45-65 years, the percentage of current hormone therapy users dropped by 16%. Among 
current hormone therapy users, the percentage of combined conjugated estrogen/progestogen 
users decreased by 41 % (P=0.008) after the publications of the WHI trial and the Heart and 
Estrogen/Progestin Replacement Study II (Clanget et al. 2005). Although several studies 
have documented the efficacy of postmenopausal hormone therapy, results from WHI trial 
have underscored the continuing need for research into new treatments for postmenopausal 
women. 
a. Homocysteine and isoflavones 
Data on the effect of isoflavones on Hcy have been relatively few and inconsistent. In 
a recent multi-center double-blind, crossover intervention trial in postmenopausal women 
(N=89), daily consumption of a fruit cereal bar containing 50 mg soy isoflavones for eight 
weeks had no effect on plasma Hcy (Reimann et al. 2006). A prospective, randomized, 
placebo-controlled trial in hypercholesterolemic men (N=89) showed that a soy based dietary 
supplement (containing 30 g soy protein, 9 g cotyledon fiber, and 100 mg isoflavones) verses 
a placebo (30 g casein) for 24 weeks did not affect Hcy. However, in a sub group, the active 
arm experienced a reduction in LDL-C and total cholesterol (Hermansen et al. 2005). Results 
from a Finland study demonstrated that daily intake of 41 g of soy protein in the form a 
yoghurt had no effect on plasma Hcy in a population of men (18-75 years) and 
postmenopausal women (45-70 years). However, significant decreases in total cholesterol, 
LDL-C, non-HDL-C, and for total cholesteroUHDL-C ratio were observed (Puska et al. 
2004). In an observational study in premenopausal Japanese women (N=201), soy product 
intake (soy protein 9.0 g/d; soy isoflavones 30 mg/d) assessed by a dietary questionnaire was 
inversely associated with serum Hcy, but this relation attained significance (P=0.04) only 
when age and total energy intake were controlled (Nagata et al. 2003). Interesting results 
from a randomized crossover trial by Jenkins et al. (2002) revealed that consumption of low-
(10 mg/d) but not high-isoflavone foods (73 ± 3 mg/d) for one month decreased Hcy 
concentration. However, when the authors pooled data from low- and high-isoflavone phases, 
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there was a significant decrease in plasma Hcy (P=0.044) during the soy phase but not the 
control phase. 
Evaluating the molecular mechanism underlying the protective effect of isoflavones, 
Fuchs et al. (2006) found that both an extract of soy protein and a combination of two 
isoflavones, daidzein and genistein, in a concentration similar to the native soy extract, 
inhibited Hcy-induced apoptosis of endothelial cells to the same extent. However, the soy 
protein extract and the isoflavones affected different cellular target proteins. In an earlier 
study by the same group, Fuchs et al. (2005) showed that genistein reversed Hcy (25 
µmol/L)-induced change in proteins involved in metabolism, detoxification, and gene 
regulation. Additonally, genistein inhibited Hcy-mediated apoptotic cell death as indicated by 
inhibition of DNA fragmentation and chromatin condensation. 
Isoflavones from sources other than soy have been researched as well. Ina 12 week 
intervention in 25 menopausal women suffering from severe hot flushes and night sweats, 
consumption of a combination of isoflavones from kudzu and red clover decreased hot 
flushes by 46% and there was a modest but not significant improvement in Hcy (Lukaczer et 
al. 2005). Additonally, the ratio of 2-hydroxyestrone-to-16 alpha-hydroxyestrone, a proposed 
marker of breast cancer risk, also improved significantly. 
b. C-reactive protein and isoflavones 
Because of the structural and functional similarity that isoflavones share with 
estrogen, it has been hypothesized that isoflavone consumption might exert a 
cardioprotective effect. The reduction in circulating inflammatory marker concentrations by 
estrogen may be one of the mechanisms by which premenopausal women are protected 
against CVD (Hall et al. 2005). In adouble-blind, placebo controlled study in 
postmenopausal women (N=117) consuming soy-derived isoflavones (50 mg/d) for eight 
weeks, isoflavones lowered elevated (>1 mg/L) CRP (Hall et al. 2005). In contrast, Nikander 
et al. (2003) found that isoflavone (114 mg/d) intake had no effect on CRP in 
postmenopausal women (N=56) with a history of breast cancer. Likewise, Jenkins et al. 
(2002) reported no significant effects of a high- (73 mg/d) or low-isoflavone soy-based diet 
for one month on CRP in postmenopausal women. Similarly, D'Anna et al. (2005) 
determined that genistein (54 mg/d) supplements consumed by healthy postmenopausal 
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women (N=90) for six months had no effect on CRP. Consistent with these findings, neither 
dietary soy isoflavones nor conjugated equine estrogen had any effect on CRP determined at 
the end of a three-year study in ovariectomized monkeys consuming a moderately 
atherogenic diet (Register et al. 2005). 
Hilpert and coauthors (2005) showed that a diet containing 25 g/d soy protein (+ 90 
mg/d isoflavones) did not produce a change in CRP compared to a control diet in moderately 
hypercholesterolemic men (N=18) and postmenopausal women (N=14) receiving hormone 
therapy. Similar work by Teede et al. (2004) in postmenopausal women and by McVeigh et 
al. (2006) in healthy young men found no effect of soy protein isolate with different doses of 
isoflavones on circulating CRP concentration. Additionally, Ryan-Borchers and colleagues 
(2006) also found that neither soy milk with isoflavones nor isoflavones provided as a 
supplement for 16 weeks had any effect on CRP in healthy postmenopausal women. 
However, there were significant changes in markers of oxidative stress, suggesting a 
protective effect of isoflavones. 
2.Osteoporosis and Isoflavones 
In the post era after the publication of the Heart and Estrogen/Progestin Replacement 
Study and WHI trials, soy isoflavones have increasingly been studied as a safe alternative to 
hormone therapy for bone loss. The low rate of hip fracture in Asian women has been 
hypothesized to be due to the purported effect of soy isoflavones on bone (Ho et a1. 2003). 
However, the lower rate of hip fracture is likely due to the shorter hip axis length and shorter 
stature of Asian women (Chin et al. 1997). Studies conducted in postmenopausal women 
have examined biochemical markers of bone turnover and change in bone loss via changes in 
BMD and BMC at the lumbar spine and hip. 
In one of the first randomized, double-blind clinical trials on the effect of isoflavones 
on bone, Alekel and coworkers (2000) demonstrated (N=69) that 40 g/d soy protein 
attenuated bone loss from the lumbar spine of perimenopausal women, whereas the whey 
protein control group had significant loss. Regression analysis showed that the active arm had 
a positive effect on change in BMD (5.6%; P=0.023) and BMC (10.1%; P=0.0032). Contrast 
coding using analyses of covariance with BMD or BMC as the outcome showed that 
isoflavones, not soy protein, exerted this favorable effect. In a randomized, double-blind, 
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placebo-controlled trial by Lydeking-Olsen et al. (2004) in postmenopausal women (N=107), 
significant lumbar spine bone loss occurred in the control group (P<0.01) and in the group 
that consumed isoflavone-rich soy milk and applied progesterone cream (P<0.01 for BMD 
and P<0.05 for BMC). The only beneficial effect of the soy only treatment was that it 
prevented bone loss in the lumbar spine. No changes were seen in the femoral neck BMC and 
BMD or in markers of bone formation and resorption among different treatments. Potter et al. 
(1998) studied hypercholesterolemic, postmenopausal women (N=66) in which they reported 
a significant (P<0.05) increase in the lumbar spine BMC and BMD at the end of 24 weeks in 
the 90 mg soy isoflavone group. Again, there was no change in the proximal femur (hip) 
region. Chen et al. (2003) examined the effect of two doses of soy isoflavones (40 mg and 80 
mg) compared to a placebo in postmenopausal Chinese women (N=203). After one year, 
researchers found an increase in BMC at the total hip and trochanter in the 80 mg isoflavone 
group (P<0.05). Further analysis revealed that the positive effect of soy isoflavones was 
observed only among women with lower (median or less) initial baseline BMC. In contrast, 
Kreijkamp-Kaspers et al. (2004) found no effect of 99 mg of soy isoflavones on BMD of 
spine or hip in older (60-75 years) postmenopausal women (N=175). Arjmandi et al (2005) 
examined the effect of an active treatment containing 25 g soy protein with 60 mg of soy 
isoflavones compared to a control. There was a decrease (albeit not significant) in whole 
body and lumbar spine BMC and BMD in both soy and control groups. These researchers 
reported an increase in serum markers of bone formation in both treatments (casein control 
vs. soy, respectively): bone-specific alkaline phosphatase activity (28% vs. 26°Io), insulin-
like growth factor-I (13°Io vs. 26°Io), and osteocalcin (95% vs. 103%). However, there was no 
change in either group in urinary deoxypyridinoline, amarker of bone resorption. 
Several studies have examined changes in markers of bone formation and resorption. 
In an Iranian study, postmenopausal women were supplemented with 35 g of soy protein 
containing 98.3 mg isoflavones daily for 12 weeks. They found an increase in total serum 
alkaline phosphatase, anon-specific and insensitive marker of bone formation, and a 
decrease in urinary deoxypyridinoline, amarker of bone resorption (Roudsari et a1. 2005). In 
other similar studies using 40 mg of isoflavones, there were either no significant differences 
(Dalais et al. 2003) or no effect on markers of bone resorption (Mori et al. 2004). In a 
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randomized, placebo-controlled crossover clinical trial, Harkness et al. (2004) supplemented 
postmenopausal women (N=19) with 110 mg/day isoflavones for a period of six months. 
They found a 37% decrease in urinary concentrations of type 1 collagen alphal-chain helical 
peptide, a marker of bone resorption, and a significant (P<0.05) increase in mean spine 
BMD. 
A few observational studies have examined the relationship between intake of soy 
foods and BMD or fracture risk. Kritz-Silverstein and Goodman-Gruen (2002) examined the 
relationship between dietary isoflavone intake and bone density at the lumbar spine and hip 
and markers of bone turnover in postmenopausal women (N=208). They reported that after 
adjustment for covariates, there was a trend (P=0.07) whereby women with the highest level 
of isoflavone consumption had greater bone density at the spine. In another study, Somekawa 
et al. (2001) found that after adjustment for years since menopause and weight, lumbar spine 
BMD was significantly higher in the highest quartile (50— >65 mg/day) compared with 
lowest intake quartile (<35 mg/day) of isoflavone intake. Another study in early mid-life (30-
40 years) Hong Kong Chinese women (N=132) observed a significantly higher spinal BMD 
in women in the fourth verses first soy isoflavone intake quartile after adjusting for 
covariates (Ho et al. 2001). Multiple linear regression analysis showed that soy isoflavones, 
together with known covariates, accounted for 24% of the variance in spinal BMD. Likewise, 
baseline data analysis from the Study of Women's Health Across the Nation, a US 
community-based cohort study in 42-52 year old women (Greendale et al. 2002), revealed 
that Japanese premenopausal women in the highest tertile of genistein intake had 7.7% and 
12%, respectively, greater spine and femoral neck BMD compared to women in the lowest 
tertile. Among Chinese women, no association was found between genistein intake and 
BMD, probably because their median intakes (3511 µg/day) were nearly half that of the 
Japanese women (7151 µg/day). Zhang and colleagues (2005) examined the relationship 
between usual soy food consumption and fracture incidence in 24,403 postmenopausal 
women who had no history of fracture or cancer in the Shanghai Women's Health Study. 
After adjustment for age, major risk factors for osteoporosis, socioeconomic status, and other 
dietary factors, the relative risk of fracture ranged from 0.63 to 1.00 (P<0.001 for trend) in 
the highest to lowest quintiles respectively of soy protein intake, with a more pronounced 
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inverse association among women in early menopause. Similar results were also found for 
isoflavones. 
Taken together, results of these studies suggest that isoflavones may prevent bone 
loss from the lumbar spine in postmenopausal women, who may otherwise be expected to 
lose 2-3 °Io of bone yearly. Such attenuation of bone loss, particularly if started during the 
early postmenopausal years and continued through menopause, could translate into a 
decreased risk for osteoporosis. Since abone-remodeling cycle ranges from 30-80 weeks 
(Heaney 1994), along-term clinical trial is needed to determine whether soy isoflavones will 
prevent bone loss and possibly favor bone formation. 
H. SUMMARY 
In summary, CVD and osteoporosis are major public health problems that frequently 
coexist and share a common mechanistic link. Hcy and CRP are emerging as novel risk 
factors for both CVD and osteoporosis in mid-life women. These novel risk factors also have 
common mechanisms for their effect on atherosclerotic CVD. These include: 1) endothelial 
cell damage and dysfunction, 2) monocyte activation and recruitment, and 3) vasodilation. 
However, Hcy and CRP are thought to affect osteoporotic risk by different mechanisms that 
are not yet completely understood. Additionally, there have been no studies examining the 
relationship between Hcy and CRP and trabecular bone, the type of bone that is preferentially 
lost with menopause. Our research team is currently investigating the relationship between 
total Hcy, CRP, cortical, and trabecular bone in healthy postmenopausal women. 
Hormone therapy has a favorable effect on Hcy but tends to increase CRP 
concentration in mid-life women. Alternatives for hormone therapy that reduce CVD and 
osteoporotic risk but do not impose further risk, as is associated with hormone therapy, are 
currently being investigated. There have been a paucity of population-based data on the 
effects of these alternative forms of therapy on postmenopausal women. Soy protein, 
particularly in combination with isoflavones, has been documented to produce an improved 
lipid profile. Isoflavone supplementation has been shown to have a modest bone-sparing 
effect but there have been few well-designed studies of sufficient duration to reach definitive 
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conclusions. More research is needed to determine whether isoflavones preserve or perhaps 
increase BMD in mid-life women. 
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Relationship of Trabecular and Cortical Bone to Circulating Total Homocysteine and 
C-Reactive Protein in Postmenopausal Women 
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ABSTRACT 
Background: Homocysteine (Hcy) and C-reactive protein (CRP) are established risk factors 
for atherosclerotic cardiovascular disease and are emerging as novel ri sk factors for 
osteoporosis. 
Objectives: The primary purpose of this study was to determine whether total Hcy and CRP 
concentrations are associated with trabecular and/or cortical bone mineral content (BMC) or 
bone mineral density (BMD) in postmenopausal women. The secondary objective was to 
determine the body composition and nutritional status indices (dietary and circulating) and 
key biologic factors related to total Hcy and CRP. The tertiary purpose of this study was to 
examine changes in total Hcy and CRP over one year. 
Methods: We enrolled healthy postmenopausal women (N=242) as part of a randomized, 
double-blind, placebo-controlled multi-center clinical trial designed to examine the effect of 
two doses of isoflavones extracted from soybeans on bone loss over three years in early 
postmenopausal women. We assessed volumetric BMD at the distal tibia and femur (1/3 site) 
using peripheral quantitative computed tomography (pQCT) in a subset of women (N=184 
for distal tibia; N=237 for 1/3 femur site). Total proximal femur and lumbar spine (L1-L4) 
BMC and BMD, as well as overall body composition, were assessed via dual-energy x-ray 
absorptiometry. We assessed plasma total Hcy, serum CRP, intracellular folate, serum folate, 
and vitamin B 12 • 
Results: Total Hcy and CRP did not contribute to the variability in trabecular BMC of the 
distal tibia or cortical BMC of the 1/3 femur site using pQCT. Approximately 22°Io of the 
variability in trabecular BMC was accounted for by weight, hemoglobin, serum uric acid, and 
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blood glucose. Study site, weight, and age accounted for about 14°10 Of the variability in 
cortical BMC. The overall variability (19°10; p<0.0001) in total Hcy was accounted for by 
serum vitamin B 12 and creatinine; the overall variability (28%; p<_0.0001) in CRP was 
accounted for by serum iron, overall percent body fat, serum uric acid, triglycerides, and 
white blood cell count. Total Hcy and CRP increased, while serum vitamin B12, serum folate, 
and intracellular folate decreased over a one year period. 
Conclusion: Total Hcy and CRP were not related to trabecular or cortical bone, but this may 
be because these women were healthy and non-osteoporotic. Since hemoglobin was a 
significant contributor to trabecular BMC, while iron was a significant contributor to CRP, it 
is possible that inflammation may mediate the relationship between iron and trabecular 
BMC. 
Key Words: Homocysteine, C-reactive protein, pQCT, trabecular bone, cortical bone, 
osteoporosis 
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INTRODUCTION 
Osteoporosis and atherosclerotic cardiovascular disease (CVD) are major public 
health problems that often coexist and account for significant morbidity and mortality in 
postmenopausal women. The postmenopausal period typically occupies one-third of a 
woman's life, with more than 40 million women in the United States now in the 
postmenopausal phase (Hargrove and Eisenberg 1995). Homocysteine (Hcy) is emerging as a 
novel risk factor for osteoporosis in mid-life women, with the increase in osteoporosis among 
those with homocystinuria suggesting that a high serum Hcy concentration may weaken bone 
(van Meurs et al. 2004). Typically, Hcy increases with age (Ganji and Kafai 2003) and is 
higher in post- than premenopausal women (Hak et al. 2000). Additionally, estrogen 
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deficiency during menopause is associated with increased release of bone-resorting 
cytokines, particularly interleukin-6 (IL-6) by bone marrow cells (Bismar et al. 1995). 
Atherogenesis and osteoporosis consist of an inflammatory component, thus providing the 
biological plausibility for the potential use of CRP, a proinflammatory risk factor for CVD, 
as a marker of both atherogenesis and osteoporotic risk. 
At the time these data were analyzed, no studies were published to examine the effect 
of total Hcy and CRP on trabecular and cortical bone separately. This is of primary 
importance as trabecular bone reflects metabolically active bone, which is preferentially lost 
during menopause and thus is of interest in assessing early osteoporotic risk (Takagi et al. 
1995). Peripheral quantitative computed tomography (pQCT) offers a novel, noninvasive 
(Grampp et al. 1995), accurate (Ebbesen et al. 1997), and precise (Sievanen et al. 1998) 
method to assess volumetric BMD, bone size, cortical geometry (Rauch et al. 1999), and 
apparent trabecular structure and connectivity (Takagi et al. 1995). In addition, determination 
of volumetric (three dimensional) BMD via pQCT provides a more accurate assessment of 
trabecular bone than areal (two dimensional) BMD via dual energy x-ray absorptiometry 
(DXA). The purpose of this analysis was to investigate the relationship of Hcy and CRP to 
trabecular and cortical bone in a sample of healthy postmenopausal women. We 
hypothesized that Hcy would be inversely associated with trabecular bone, whereas CRP 
would be inversely related to either trabecular or cortical bone as assessed by pQCT. We 
determined the body composition and nutritional status indices (dietary and circulating) and 
key biologic factors related to total Hcy and CRP. We also assessed change in CRP, total 
Hcy, serum vitamin B12, serum folate, and intracellular folate over the course of one year in 
these postmenopausal women. 
MATERIALS AND METHODS 
Research Design 
We enrolled healthy postmenopausal women (45.8-65.0 years of age) as part of a 
randomized, double-blind, placebo-controlled multi-center (Iowa State University [ISU], 
Ames, IA and University of California at Davis [UC-Davis], Davis, CA) clinical trial. This 
parent study (Soy Isoflavones for Reducing Bone Loss; SIlZBL) is designed to examine the 
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effect of two doses of isoflavones extracted from soybeans on bone loss during the course of 
three years in 242 at-risk early postmenopausal (e.g., less than 10 years since their last 
menses) women (Elders et al. 1989). Eligible participants (non-osteoporotic, without diseases 
or conditions, not taking hormones or medications) have been randomly assigned to one of 
three treatment groups: isoflavone-rich soy extract with 80 mg of isoflavones, with 120 mg 
of isoflavones (aglycone form), or placebo without isoflavones. We have collected and are in 
the process of collecting data from women in the laboratory at baseline, six, 12, 24, and 36 
months. As part of an ancillary project, this report examines total Hcy and CRP at baseline 
and at six and 12 months. We are also examining the relationship between total Hcy and CRP 
and bone (trabecular and cortical) using pQCT. 
Subject Screening, Selection, and Characteristics 
We recruited subjects throughout the state of Iowa and the Sacramento region in 
California through direct mailing lists, stories in local newspapers, local/regional radio 
advertisements, astory on a local television channel, community announcements, 
cooperative extension nutrition and health field specialists, and mailings/flyers at local school 
systems, medical centers/clinics, grocery stores, university campus, public libraries, local 
women's groups, and local businesses. We screened women who responded (N=5,255) to 
outreach materials initially via a telephone questionnaire to identify healthy women who 
went through a natural menopause (cessation of menses nine months to ten years), were _< 65 
years of age, non smokers, and had a body mass index (BMI, kg/m2) ranging from 18.5 
through 29.9 (inclusive). We excluded women with currently diagnosed or previous history 
of bone disease, renal disease, urinary stones, cancer, malignancy or tumor of any kind, 
cardiovascular disease, diabetes mellitus, respiratory disease, parathyroid disease, thyroid or 
liver disease, and/or those women who had afirst-degree relative with breast cancer. 
Additionally, we also excluded women currently using chronic medications, such as 
cholesterol-lowering or anti-hypertensive medications, or women who refused to cease 
taking herbal therapies and/or nutritionaUdietary supplements. We also excluded vegans and 
high alcohol consumers (>7 servings per week). Use of oral hormone or estrogen therapy, 
selective estrogen receptor modulators, or other hormones within the last 12 months, use of 
estrogen or progestogen creams or calcitonin within the last six months, use of antibiotics 
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within the last three months, and/or any previous use of bisphosphonates were grounds for 
exclusion. We also excluded subjects with excessive vasomotor symptoms from the study. 
Because the purpose of the parent study is to examine the effect of isoflavones on bone, 
subjects were required to consume one of three treatments daily for three years, discontinue 
use of non-study nutritional supplements, and avoid consuming isoflavone-rich foods. 
Women who met the initial criteria via telephone (N=677) attended apre-baseline 
appointment at the testing center to determine additional entry criteria. We measured height 
and weight to confirm BMI status. We used DXA to determine BMD of the lumbar spine and 
left proximal femur. Women with evidence of osteopenia or osteoporosis based on lumbar 
spine and/or proximal femur BMD (using > 1.5 SD below the young adult mean as cut-offs 
and women with evidence of previous or existing spinal fractures were excluded. We also 
excluded women with spine and/or femur BMD > 1.0 SD above the mean. If a woman 
qualified based on her BMD, our phlebotomist drew blood for a chemistry profile. We 
excluded women if their fasted blood values indicated diabetes mellitus (fasting blood 
glucose > 126 mg/dl), abnormal renal, liver and/or thyroid function, or abnormal lipid profile 
(low density lipoprotein-cholesterol > 160 mg/dl; triacylglycerol >200 mg/dl). To be qualified 
for the study, each woman needed to undergo a transvaginal ultrasound at area clinics (ISU: 
McFarland Clinic, Ames IA; UC-Davis: Mather vA, Mather, CA). Each woman was 
required to have an endometrial thickness < 5.0 mm to qualify. However, women with an 
endometrial thickness between 5.0 and 6.0 mm had to undergo an endometrial biopsy that 
proved normal to be considered eligible. We enrolled subjects who met all entry criteria 
(N=242) in the parent study (Figure 1). 
The study protocol, consent form, and subject-related materials were approved by 
ISU Human Subjects Review Committee (Institutional Review Board; IRB ID# 02-199) and 
the UC-Davis IRB (ID# 200210884-2). Approvals for the DXA and pQCT procedures were 
obtained from each institution's IRB and appropriate safety boards. We obtained informed 
consent from all women at the start of pre-baseline screening. 
Data Collection 
At the pre-baseline visit, trained interviewers administered three questionnaires: 
nutrition history, health and medical history, and reproductive history. Each subject filled out 
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a historical physical activity questionnaire at home; this questionnaire was reviewed by 
interviewers during the baseline visit for completeness. Estrogen exposure (in years) was 
calculated for each subject by subtracting her age at menarche from her age at her last 
menstrual cycle. At the baseline testing appointment, we assessed dietary intake using asemi-
quantitative food frequency questionnaire from Block Dietary Data Systems (Berkeley, CA) 
and soy food intake using a soy food questionnaire (Kirk et al. 1999). A trained 
anthropometrist at each geographic site measured standing and sitting heights (Ayrton 
stadiometer, Model S 100; Ayrton Corp., Prior Lake, MN); weight (abco Health-o-meter; 
Health-o-meter Inc., Bridgeview, IL); waist, hip, and abdominal circumferences; sagittal 
diameter (Holtain-Kahn abdominal caliper; Holtain Ltd., Croswell, Crymych Dyfed, U.K.); 
and skeletal widths/breadths at the shoulder (biacromial), hip (biiliac), thigh (bitrochanteric) 
(Harpenden skeletal anthropometer; Holtain Ltd., Crosswell, Crymych, Dyfed, UK), and 
elbow (Gneupel Swiss made SERITEX; Rutherford, New Jersey) using anthropometers. We 
also measured resting heart rate and blood pressure using an automatic digital 
sphygmomanometer (HEM-907; Omron Healthcare, Inc., Vernon Hills, IL) after the subject 
sat quietly for at least 20 minutes. We also assessed balance and propensity to fall (using a 
one-foot stance balance test) and torso, quadriceps, and grip strength using two 
dynamometers (back strength [torso and quadriceps] : TKK 5002 Back-A; Takei Scientific 
Instruments Co., Ltd, Japan; grip strength [0 to 100 kg] : Lafayette Instrument Co., Lafayette, 
IN). Each woman collected a 24-hour urine sample the day before her testing appointment. 
Urine samples were thoroughly mixed and aliquots were frozen at -20°C for further analyses. 
Phlebotomists collected fasted (9 hours) blood samples between 7:00 and 8:00 a.m. We 
separated serum and plasma from whole blood by centrifuging for 15 minutes (4°C) at 1000 
x g and stored aliquots at -80°C until analyses. 
Bone and Body Composition Measurements 
We assessed volumetric BMD at the distal tibia and femur (1/3 site) using pQCT 
(XCT 3000; STRATEC Medizintechnik, Pforzheim, Germany, Division of Orthometrix; 
White Plains, NY) in a subset of women (ISU=122, UC-Davis=62 for distal tibia; ISU=122, 
UC-Davis=115 for femur 1/3 site). Total proximal femur and lumbar spine (Ll-L4) bone 
mineral content (BMC) and BMD were assessed via a Delphi W DXA (Hologic, Inc; 
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Bedford, MA) instrument. In addition, whole body DXA scans provided total body 
composition. 
Matching instruments at each site and daily calibration ensured that the pQCT and 
DXA instruments provided comparable results. One operator at each site performed all 
pQCT and DXA scans. Cross-training for pQCT and DXA scanning between sites has 
ensured comparable quality control. Laboratory personnel at each site were trained by the 
manufacturers' technicians and received further training on pQCT software analysis (Bone 
Diagnostic, Inc.; Fort Atkinson, WI). A research assistant at UC-Davis performed all pQCT 
scan analyses following guidelines provided by Bone Diagnostic, Inc. The ISU DXA 
operator performed all DXA scan analyses following Hologic guidelines for BMC, BMD, 
and overall body composition using software version 12.3:7. The procedures were approved 
by the State Department of Public Health in both Iowa and California. The ISU laboratory 
within-subject (n=10 per skeletal site) in vivo precision error (coefficient of variation) for 
pQCT and DXA measurements is presented in Table 1. 
Laboratory Measurements 
Total Hcy concentration was determined using a high performance liquid 
chromatography (HPLC) method adapted from Araki and Sako (1987) and Ubbink et al. 
(1991). The total Hcy in plasma consists of free Hcy (i.e., reduced plus oxidized Hcy in the 
non-protein fraction of plasma) and protein-bound Hcy (Araki and Sako 1987). The thiol 
compounds in heparinized plasma, which were reduced or liberated from plasma proteins 
with tri-n-butylphosphine (Sigma, St. Louis, MO), were derivatized with a thiol-specific 
fluorogenic reagent, ammonium 7-flourobenzo-2-oxa-1,3-diazole-4-sulphonate (Sigma, St. 
Louis, MO). N-Acetylcysteine (1 mM) was added to the plasma samples prior to 
derivatization as an internal standard. All derivatized samples were filtered (ISO-DISC 
PTFE-4-2, 4 mm x 0.2 µm; SUPLECO, Bellefonte, PA) into vials and frozen at -20°C until 
use. Derivatized samples (100 µl) were analyzed on HPLC (Beckman Coulter System Gold 
126 Solvent Module and Beckman Coulter System Gold 508 Autosampler; Fullerton, CA) 
using a reverse LC-18 column (SUPELCOSILTM; 25cm x 4.6mm, 5µm; SUPLECO, 
Bellefonte, PA), protected by an LC-18 guard column (SUPELCOSILTM LC-18 Supelguard°
Cartridge; SUPLECO, Bellefonte, PA). The following solvents were used: (A) acetonitrile 
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(B) 0.1 M potassium phosphate (monobasic) buffer (pH 1.75 adjusted with o-phosphoric 
acid) in HPLC water. The buffers were filtered through a MAGNA, Nylon, Supported Plain, 
0.22 micron, 47 mm filter just prior to use. The final pH of the 0.1 M potassium phosphate 
(monobasic) buffer after filtering was 2.1. The initial starting conditions were 96% solvent B 
and 4% solvent A at a flow rate of 1.0 ml/min. Samples were introduced with an injection 
valve fitted with a 100 µl sample loop. At 14.10 minutes, a one minute gradient from 96% to 
84% for solvent B was applied and allowed to pump for 10 minutes. At 25.10 minutes, B was 
increased to 96% over five minutes and pumped fora 10 minute requilibration period before 
the next sample was injected. The fluorescence intensities were measured with excitation at 
385 nm and emission at 515 nm, using a JASCO FP-1520 fluorescence detector. At the end 
of each sequence, we performed a wash for 160 minutes using 100% HPLC grade water at 
1.0 ml/min. At the end of 160 minutes, we changed the pumps to 50% water and 50% 
acetonitrile for one hour at a flow rate of 1.0 ml/min. At the end of 220 minutes, initial 
conditions were restored with a five minute gradient back to 96% solvent B and 4% solvent 
A and allowed the system to requilibrate. The intraassay variability was 3.8% and the 
interassay variability was 6.3 °Io. 
CRP concentration was determined in serum using a high sensitivity sandwich 
enzyme-linked immunosorbent assay kit (ALPCO Diagnostics; Salem, NH). Intracellular 
folate, serum folate, and serum vitamin B 12 were measured using a radioactive immunoassay 
kit (MP Biomedicals; Irvine, CA). We used manufacturer-provided and in-house quality 
controls. The intraassay variability for CRP, intracellular folate, serum folate, and serum 
vitamin B12 are 3.5%, 3.2%, 3.4%, and 3.4%, respectively. The interassay variability for 
CRP, intracellular folate, serum folate, and serum vitamin B 12 are 6.0%, 11.8%, 10.1 %and 
10.1 %, respectively. Blood samples were analyzed by a certified clinical laboratory 
(LabCorp; Kansas City, Kansas at the ISU site and the UC-Davis Medical Center Laboratory; 
Sacramento, CA at UC-Davis site) for a complete blood count (CBC) with differential, 
general chemistry panel (ChemScreen), and thyroid screen (thyroid stimulating hormone 
(TSH) with reflex to free thyroxine (T4) if TSH was abnormal). 
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Subject Follow-up 
For the parent project, women underwent serial testing through three years of 
treatment. However, we are reporting data only through the first year in this ancillary project. 
Since the parent project follows an intent-to-treat model, our current analyses included all 
eligible women at baseline, regardless of whether or not they were compliant with study 
protocol. This study includes three women who did not take treatment tablets, but returned 
for testing visits as part of the intent-to-treat model: one was diagnosed with breast cancer 
(ISU), one experienced a severe gastrointestinal adverse event (UC-Davis), and one chose to 
consume soy products rather than treatment tablets (UC-Davis). In addition, 13 women were 
lost to follow-up: two at ISU after baseline, seven at UC-Davis after baseline, and four at 
UC-Davis after six months. Thus, the sample size for this study varied across time points: 
N=242 at baseline, N=23 3 at six month, N=229 at 12 month (Figure 1) . 
Power Analysis and Statistical Analyses 
Power analysis for this study is based on the NIAMS-funded project (#ROl 
AR046922-01 A2), reflecting a random effects repeated measures (Laird and Ware 1982) 
regression model of change in lumbar spine BMD via DXA as the outcome variable. Our 
sample size is fixed at 184 for this project. Statistical analyses were performed using SAS 
(version 9.1; Cary, NC) with results considered statistically significant at p<0.05. Descriptive 
statistics included means for normally distributed data (age, years since menopause, estrogen 
exposure, body size, body composition, and bone data) and medians for data that were not 
normally distributed (total Hcy, serum CRP, and dietary intake). We excluded CRP values 
> 10 mg/L for all inferential statistics, based on recommendations from the Centers for 
Disease Control and the American Heart Association (Pearson et al. 2003). To examine the 
relationship between total Hcy and CRP versus bone, we used Spearman's rho correlation 
analyses. In all regression models, study site was included as an obligatory variable to 
account for potential site differences. In modeling the outcomes of interest, we removed 
variables that exhibited multicollinearity as indicated by the variance inflation factor. We 
performed multiple regression analyses to assess the combined contribution of factors related 
to volumetric BMC and BMD (weight, age, blood glucose, hemoglobin, serum uric acid, 
plasma total Hcy, serum CRP, and total calcium [dietary plus supplemental] intake). Classes 
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of variables in modeling the outcomes of baseline trabecular and cortical BMC and BMD 
included all covariates that were biologically plausible and/or significantly related to bone in 
the Spearman's rho correlation analysis. We have presented the best models for trabecular 
and cortical BMC because these models were better than the BMD models. Given that total 
Hcy and CRP are important CVD risk factors that also possibly contribute to osteoporosic 
risk, we examined contributing factors to total Hcy and CRP. The following variables were 
initially included in the model: serum vitamin B12, serum or intracellular folate, serum 
creatinine, serum uric acid, and specific dietary factors (vitamin B6; carbohydrate [because 
grains are fortified with folate]; magnesium, phosphorus, dietary or total calcium, and 
vitamin C [as indicators of an overall adequate diet]; retinol; and riboflavin). In modeling 
CRP, we initially included the following variables: age, whole body percent fat, waist 
circumference, white blood cell count, serum iron or total iron binding capacity, serum uric 
acid, and total cholesterol/HDL-C ratio. Similar to the BMC models, we included all 
variables that were biologically plausible and/or significant in the Spearman's rho correlation 
analysis for total Hcy and CRP. To determine whether change over the course of time 
(baseline to one year) was significantly different from zero for CRP and total Hcy (as well as 
intracellular folate, serum folate, and vitamin B 1~), we performed a matched pair analysis. 
Since these circulating variables were not normally distributed, we performed a Wilcoxon 
signed-rank test. It is important to note that the matched pair analysis does not take treatment 
into account; these results are presented merely as a basis for discussion. 
RESULTS 
Subject Characteristics 
The baseline characteristics of women are described in Table 2 and Table 3. At the 
start of this study, women were 65 or younger and were within 10 years of menopause. The 
majority of women were Caucasian at each site. The vast majority of the subjects reported 
that they were not vegetarians, with only four being vegetarian (three pesco, one lacto-ovo). 
More than half of the subjects reported a family history of cardiovascular disease, while one 
third reported a family history of osteoporosis and/or a personal history of bone fracture. The 
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most common form of hormone therapy use was combined estrogen plus progestogen 
therapy, with a wide range of duration in general for any formula. 
Approximately half of the women had a BMI <25.0 kg/m2. Although the mean BMI 
was comparable between the two sites, there was greater variability in BMI at UC-Davis. 
This was because at UC-Davis two women were below the exclusion criteria of 18.5 and 
eight women were above the exclusion criteria of 29.9. Consequently, body composition 
measures, particularly those reflecting the fat compartment, were more variable at the UC-
Davis than at the ISU site. Integral bone (cortical and trabecular) measurements assessed via 
DXA and volumetric bone measurements (distal tibia reflecting trabecular bone and 1/3 
femur site reflecting cortical bone) assessed via pQCT are shown in are presented in Table 4. 
In examining the DXA data and the pQCT data, it appears that the UC-Davis BMC data have 
greater variability than the ISU data, whereas this greater variability is no longer apparent for 
the BMD data at parallel bone sites. Thus, once bone area was taken into account, the 
variability differences in the BMD data are no longer apparent. All bone measures were 
normally distributed and thus mean values are reported. We reported median values on 
circulating analytes as they were not normally distributed (Table 5). Approximately 48% of 
the subjects had normal CRP (<1 mg/L), 36% had moderately elevated CRP (1-3 mg/L), and 
16°Io had high CRP (>3 mg/L) values. We conducted intracellular folate analysis on 230 
women (seven samples at ISU were incorrectly processed; one sample at UC-Davis was 
missing; two at ISU and two at UC-Davis were missing hematocrit values). The median 
dietary intake for carbohydrate, protein, riboflavin, vitamin B6, and vitamin B IZ 
approximated the dietary reference intakes (DRIs) for each of these nutrients. However, this 
was not the case for fiber, vitamin A, vitamin E, folic acid, magnesium, or calcium. The 
median total calcium (dietary and supplemental) intake at baseline was 1185 mg daily (Table 
6) approximating the calcium DRI (1200 mg/day) for postmenopausal women. At both sites 
combined, lifetime calcium intake from dairy products decreased consistently from 
childhood, when milk intake was the highest, to mature adulthood, with this decline being 
particularly pronounced for the UC-Davis women. The percentage of women who took 
calcium supplements was 61..5°Io at ISU and 67.5% at UC-Davis. 
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Correlation Analyses 
Correlation coefficients between bone measurements versus CRP and total Hcy are 
shown in Table 7. The highest positive correlation (r=0.192, p=0.003) was observed between 
CRP and total proximal femur BMD assessed via DXA. In addition, CRP was also correlated 
with distal tibia trabecular BMD (r=0.178, p=0.017) assessed via pQCT. Although our 
women did not report any chronic diseases, approximately 32 to (n=77) had CRP values > 1.8 
mg/L. In a subsample analysis including women with elevated CRP (> 1.8 mg/L), Spearman 
rho's correlation analysis revealed that CRP was significantly and negatively correlated with 
spine BMC (r= -0.227; p<_0.05). We found no relationship between total Hcy and bone 
measurements in these healthy postmenopausal women. 
Regression Analyses 
Since trabecular bone, cortical bone, total Hcy, and CRP were our primary outcomes 
of interest, we performed further analyses to examine factors contributing to their variability. 
Since the BMC was better than the BMD model for both trabecular and cortical bone, we 
have presented only the BMC regression models. Factors contributing to the variability of 
trabecular and cortical BMC are presented in Table 8. We initially included the following 
variables in the model: age, blood glucose, hemoglobin, serum uric acid, weight, serum 
CRP, and total calcium. After variable elimination was completed, multiple regression 
analyses revealed that 22% of the variability in trabecular BMC (F=9.59, p<_0.0001) was 
accounted for by hemoglobin, uric acid, weight, and fasting blood glucose. Although site did 
not reach significance, we kept site in the model to account for potential. site differences. 
Serum uric acid (p=0.0027) contributed negatively to trabecular BMC. In contrast, baseline 
body weight (p<0.0001) and hemoglobin (p=0.0006) contributed positively to trabecular 
BMC. Variables that remained in the model (except site) were significant atp<0.10. We used 
the same variables for the cortical BMC at 1/3 femur site that were initially included in the 
trabecular BMC model. Site, age, and weight emerged as significant positive contributors to 
cortical BMC and together explained 14°Io of the variability in cortical bone (F=12.54, 
p_<0.0001). Site accounted for the greatest proportion of the variability (9%), while age and 
weight contributed a smaller percentage. 
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In the final total Hcy model (Table 9), approximately 19% of the variability 
(F=17.72, p<_0.0001) was accounted for by serum vitamin B 12 (12%) and creatinine (6°Io). 
Serum vitamin B12 (p<_0.0001) contributed negatively to total Hcy concentration. In the final 
CRP model (Table 9), whole body percent fat (5%), uric acid (3°Io), and triglycerides (3%) 
were the most significant and positive contributors to circulating CRP concentration. 
Additionally, white blood cell count (2°Io) was positively and serum iron (2°Io) was negatively 
related to CRP. 
Longitudinal Analyses 
The mean change in serum CRP, plasma total Hcy, intracellular folate, serum folate, 
and serum vitamin B12 during the course of one year is shown in Figure 2. Wilcoxon signed-
rank test revealed that CRP decreased significantly from baseline to six months (-0.2 mg/L; 
p=0.05) but increased overall from baseline to one year (0.3 mg/L; p=0.0035). On the other 
hand, total Hcy increased significantly at the end of six months but did not change 
significantly thereafter. Similarly, serum folate, intracellular folate, and vitamin B12 
decreased significantly by six months but no change was observed after six months. 
DISCUSSION 
Menopause contributes to significant risk in developing osteoporosis (Scheiber and 
Rebar 1999) and atherosclerotic CVD (Welty 2001) in postmenopausal women. Many risk 
factors including elevated Hcy (Hak et al. 2000) and CRP emerge after menopause. To our 
knowledge, this is the only published study examining the relationship between total Hcy and 
CRP versus trabecular and cortical bone in healthy postmenopausal women. A couple of 
studies have related high total Hcy to a low BMD (Gjesdal et al. 2006; McLean et al. 2004). 
However, no studies have examined the relationship between total Hcy and trabecular or 
cortical bone separately. 
Contrary to previous findings (Gjesdal et al. 2006; McLean et al. 2004), we did not 
demonstrate a relationship between circulating total Hcy and integral bone. Although we 
hypothesized that total Hcy would be inversely associated with trabecular bone, correlation 
analysis did not reveal any association between total Hcy and trabecular bone (r=-0.041, 
p=0.58). However, the vast majority of women in our study had normal total Hcy, whereas 
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previous epidemiological studies have demonstrated an increased risk of osteoporotic 
fracture only in subjects with high Hcy (>15 µmol/L). For example, in the Hordaland 
Homocysteine Study (Gjesc~al et al. 2006), the multiple adjusted odds ratio for low BMD was 
1.96 in those with high (>15 µmol/L) compared with low (<9 µmol/L) Hcy. Similarly, the 
Framingham Study (McLean et al. 2004) showed that subjects in the highest quartile 
(18.6±6.4 µmol/L) had a greater risk of hip fracture than those in the lowest quartile (7.6±1.0 
µmol/L) of total Hcy. Plasma total Hcy concentration was slightly higher (7.6 ± 2.1 µmol/L) 
in our study than that recently reported for women (6.8 ± 0.1 µmol/L) from the 2001-2002 
NHANES data (Ganji and Kafai 2006), but was comparable to the lowest quartile of total 
Hcy for women (7.6±1.0 µmol/L) in the Framingham Study (Gjesdal et al. 2006). Only four 
women in our study had high (>15 µmol/L) plasma total Hcy, possibly explaining why we 
did not detect a relationship between Hcy and bone in these healthy postmenopausal women. 
Nonetheless, we identified a number of known and unconventional factors that 
contributed to the variability in trabecular BMC. Hemoglobin emerged as a strong 
contributor to trabecular but not cortical BMC. This may be because trabecular bone is more 
highly vascularized, is well innervated, and is responsible for hematopoiesis and mineral 
homeostasis. Subjects with a higher hemoglobin concentration may have better oxygen 
delivery to all tissues, including bone, thereby increasing trabecular BMC. Reporting similar 
results, Cesari et al. (2005) concluded that hemoglobin was significantly (positive direction) 
associated with total bone density (at the calf; p=0.03), as well as both trabecular (p=0.02) 
and cortical (p=0.03) bone density, using pQCT in older women. Interestingly, African-
American sickle cell disease (characterized by low hemoglobin concentrations) patients had 
13% lower integral BMD of the forearm, but showed no differences in trabecular bone 
(Nelson et al. 2003). Yet, the lumbar spine BMD, which is about 66% trabecular bone, was 
low in most of the young adult sickle cell patients in another study (Miller et al. 2006). One 
may speculate that a low hemoglobin concentration due to iron deficiency anemia may 
impact bone by reducing trabecular BMC. To illustrate, the lumbar vertebrae of female rats 
either on an iron restricted (12 mg Fe/kg/day) but calcium adequate (5.2 g Ca/kg diet) diet 
(Parelman et al. 2006) or an iron deficient diet (< 8 mg Fe.kg/day; Medeiros et al. 2004) had 
a lower trabecular number and greater trabecular separation using micro-computed 
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tomography. It is important to note that hemoglobin is fairly stable in postmenopausal 
women who no longer have monthly blood losses. Perhaps this is one explanation why we 
noted the strong association of hemoglobin with trabecular bone in these women. An 
explanation for the role of iron in bone formation is that iron is a cofactor for prolyl and lysyl 
hydroxylases, enzymes that catalyze an ascorbate-dependent hydroxylation of prolyl and 
lysyl residues. These steps are essential to collagen crosslinking in bone by lysyl oxidase 
(Tuderman et al. 1977). Serum ferritin, a marker of iron stores, is a better indicator than 
hemoglobin of iron status and may also have shown this relationship .to bone. We measured 
serum ferritin only in the ISU women, but plan to measure serum ferritin in the UC-Davis 
women as well. Ferritin will allow us to distinguish between iron status and inflammation in 
these women and perhaps will be related to trabecular bone. The negative relationship 
between circulating uric acid and trabecular BMC may parallel the relation between low 
BMD and elevated uric acid excretion, typical in calcium renal stone formers (Pietschmann 
et al. 1992). Thus, the relationship between uric acid and trabecular BMC may illustrate the 
importance of kidney function in bone health. Pertinent to our results, Ensrud et al. (1997) 
revealed that compared with heavier women, thin women had a nearly two-fold increase in 
the age-adjusted risk (relative risk=1.93) of hip fracture. Additionally, the Study of 
~steoporotic fractures in older women and the Osteoporotic Fractures in Men Study 
demonstrated higher rates of hip bone loss among women (Ensrud et al. 2003) and men 
(Ensrud et al. 2006) undergoing weight loss. A very low body weight may exacerbate the 
already hypo-estrogenic state of postmenopausal women, contributing to an even greater 
imbalance between bone resorption and bone formation. This imbalance maybe reversed with 
weight gain and as a more optimal weight is maintained, this may be associated with 
increases in BMC and BMD (Bolton et al. 2005). 
Although a few studies have demonstrated an association between CRP concentration 
and BMD or biochemical markers of bone turnover in immune (Bakri Hassan et al. 1998) 
and inflammatory (Haugeberg et al. 2006; Punzi et al. 2005) disease states, there is a paucity 
of information examining this relation in non-inflammatory conditions or in healthy 
postmenopausal subjects. Contrary to our hypothesis, we found no association between CRP 
and volumetric cortical bone at the 1/3 femur site, but it was significantly and positively 
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associated with total proximal femur BMD and distal tibia trabecular BMD. However, once 
others factors were taken into account, CRP was no longer related to trabecular BMD; yet, 
we identified factors contributing to volumetric cortical bone. A potential drawback in multi-
center clinical trials is that measurement differences between study sites may emerge. 
Nonetheless, pQCT operators were trained similarly and we did not detect a significant study 
site effect for the distal tibia. However, for the 1/3 femur site, after controlling for study site 
(9%), age and weight together accounted for about 7% of the variability in cortical BMC. It 
was rather surprising that weight was the strongest contributor to trabecular BMC, but not to 
cortical BMC via pQCT. Perhaps this was due to study site accounting for a significant 
proportion of the variability in cortical BMC, thereby diminishing the effect of weight. It is 
important to note that UC-Davis had a greater proportion of women at the upper end of the 
weight spectrum, as well as a greater proportion of older women farther from last menses 
than ISU. Perhaps the importance of study site for cortical bone may be related to the higher 
weight and age of women at UC-Davis. Yet, study site had a very low variance inflation 
factor. Sigurdsson et al. (2006) noted that with every 10 year increase in age among elderly 
women there is a 0.8% decrease in cortical BMD. The Framingham Osteoporosis Study 
(Hannan et al. 2000) and the Rotterdam Study (Burger et al. 1998) reported an annual 
decrease of 0.9% and 0.6%, respectively, in femoral neck BMD, which is about 75% cortical 
bone. 
The median CRP concentration (1.0 mg/L) in our study was similar (1.0 mg/L) to that 
reported by Koh et al (2005) in Korean women, but was slightly lower than the concentration 
(1.5 mg/L) in apparently healthy American women (Rifai and Ridker 2003). Our results 
showing a positive correlation between total proximal femur BMD and CRP do not agree 
with Koh et al. (2005), who demonstrated that higher circulating CRP was associated with 
lower femoral neck BMD in postmenopausal women. However, women from their study 
were late postmenopausal (7.7±5.7 years) compared to our women who were early 
postmenopausal (3.5±2.0 years). More importantly, in osteopenic and osteoporotic women, 
CRP was significantly greater (p<_0.014) compared with healthy postmenopausal women. 
Since we only recruited women whose BMD was within the normal range, it is possible that 
we were unable to detect a relationship between CRP and bone because our women were 
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more uniform with respect to BMD. To further explore this relationship, we used the 1.8 
mg/L cut-off value because this value was associated with osteopenia and/or osteoporosis in 
the Korean study (Koh et al. 2005). When we examined our women with CRP greater than 
1.8 mg/L, we found that lumbar spine BMC was significantly and negatively associated with 
CRP (r= -0.227; p<0.05). High CRP (> 1.8 mg/L) thus seems to be a risk factor not only for 
atherosclerotic CVD, but also for increased risk of osteoporosis. 
Our finding that total Hcy increased over a period of one year could be due to several 
possibilities. As this is an ancillary study to an NIAMS/NIH funded project, we did not 
separate out the effect of treatment in this group of women. Since two-third of the subjects 
are on active treatment (80 or 120 mg isoflavones), it may be that: 1) total Hcy increased 
with age or time since menopause, 2) treatment altered total Hcy, or 3) total Hcy increased as 
time since subjects ceased taking all forms of supplements at baseline increased. However, 
the increase in Hcy is parallel to the significant decreases in serum vitamin B 12, serum folate, 
and intracellular folate values. Interestingly, the increase in CRP at the end of one year is 
similar to the increase in CRP seen with hormone therapy (Lakoski et al. 2005, Reuben et al. 
2006). Since two-thirds of the women are on active treatment (isoflavones), it is possible that 
these compounds are exerting an estrogen-like effect by increasing CRP. It is also possible 
that CRP increased with age or time since menopause. We will not be able to determine what 
these changes are due to until we are able to unblind the trial at the end of treatment. 
Since total Hcy and CRP are risk factors for atherosclerotic CVD and perhaps 
osteoporosis, we examined the factors contributing to circulating total Hcy and CRP. In our 
analyses we only included women with a CRP value < 10.0 mg/L. According to the Centers 
for Disease Control and American Heart Association guidelines (Pearson et al. 2003), CRP 
>10.0 mg/L should be discarded and repeated in two weeks to allow acute inflammation to 
subside before retesting (Bassuk et al. 2004). Since we analyzed our samples in batch at the 
end of year one, we could not obtain another blood sample for those women with elevated 
CRP. Instead, we excluded nine CRP data points in the inferential statistics. Our finding that 
whole body percent fat, but not waist circumference as an indicator of central adiposity, was 
a strong predictor of CRP and has been shown in other studies (Gomez-Ambrosi et al. 2006; 
Manns et al. 2003; Saito et al. 2003). However, Iwasaki et al. (2006) demonstrated that both 
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visceral (r=0.55; p~~0.0001) and subcutaneous (r=0.40; p<0.0001) fat were independently 
correlated to CRP in non-diabetic men and women. Thorand et al. (2006) concluded that 
adiposity was strongly associated with low-grade systemic inflammation and was especially 
strong in women as reflected by CRP. More recently, researchers have demonstrated that 
human adipocytes also produce CRP after stimulation with inflammatory cytokines IL-1 beta 
and IL-6 and by the specific adipocytokine, resistin, thereby suggesting a link between 
obesity and inflammation (Calabro et al. 2005). 
Similar to our findings, Lee et al. (2006) demonstrated that low serum iron was 
associated with apro-inflammatory state and thus an elevated CRP concentration. Hepcidin, 
a key regulator of serum iron during inflammation, is thought to bind to its receptor, protein 
ferroporotin, which serves as a transmembrane iron channel enabling iron efflux from cells. 
The hepcidin-ferropo~-tin complex is then degraded in lysosomes and iron is not released 
from cells (mainly enterocytes, macrophages, and hepatocytes), thus leading to a decrease in 
iron absorption and a decrease in serum iron (Vyoral and Petrak 2005). This possibly 
explains the low serum iron concentration typically seen in inflammatory conditions. 
Analogous to previous findings (Yanagawa et al. 2006), we found that with increasing CRP, 
there was an increase in triglycerides. Esteve et al. (2005) explained that changes in lipid 
metabolism due to inflammation are aimed at protecting the host from acute injury and are 
mediated by cytokines. The activation of the inflammatory cascade induces a decrease in 
HDL-cholesterol, which stimulates compensatory changes, such as synthesis and 
accumulation of phospholipid-rich VLDL. These particles then bind to bacterial products and 
other toxic substances, resulting in hypertriglyceridemia. The final consequence is an 
increased accumulation of intracellular cholesterol. Additionally, CRP also influences the 
response to a low fat or high MUFA diet. Desroches et al. (2006) demonstrated that in 
subjects with high CRP, a low fat diet increased triglycerides. On the other hand, in subjects 
with low CRP, a high MUFA diet decreased triglycerides. Our finding of a positive 
relationship between serum uric acid and CRP has been reported in previous studies in 
healthy subjects (Dohi et al. 2006) and in chronic kidney disease patients (Caravaca et al. 
2005). Uric acid was found to be independently and positively correlated with CRP in 
healthy subjects (Patel et al. 2006), but unlike our study, it failed to contribute to the 
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variability in CRP. The positive relation between white blood cell count and CRP has been 
reported in the past (Byrne et al. 2004) and likely reflects that some of our subjects may have 
had an infection or some degree of inflammation at baseline. Typically during inflammation, 
there is an increase in the white blood cell count, as a result of the bone marrow reacting to 
inflammation or infection (Abramson and Melton 2000). 
Given that vitamin B12 is a co-enzyme with methionine synthase in the remethylation 
pathway of Hcy (Selhub 1999), it was not surprising that serum vitamin B12 contributed 
inversely to baseline total Hcy. Similar to our findings, other studies have also noted that 
creatinine is a predictor of total Hcy in patients on hemodialysis (Refsum et al. 2006) and in 
the general population (Righetti et al. 2006). Hcy is metabolized by the kidney and serum 
creatinine is a marker of renal function. Recent research has shown that total Hcy 
concentration is positively correlated with creatinine in the early stage of chronic renal 
failure (Cetin et al. 2006) and in elderly hospatilized patients (Rodriguez et al. 2006), but not 
in healthy populations (Taskin et al. 2006). Thus, it was surprising that serum creatinine 
emerged as a contributor to Hcy in these healthy women. 
In conclusion, total Hcy and CRP were not related to trabecular or cortical bone, but 
this may be because these women were healthy and non-osteoporotic. Nonetheless, it is of 
prime importance to examine the type of bone that is lost in hyperhomocysteinemic subjects. 
Since hemoglobin was a significant contributor to trabecular BMC, while iron was a 
significant contributor to CRP, it is possible that inflammation may mediate the relationship 
between iron status (reflected by low serum iron and/or hemoglobin concentration) and low 
trabecular BMC. 
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Table 1: Precision Error (%)for Peripheral Quantitative Computed Tomography 
(pQCT) and Dual energy X-ray Absorp~iometry (DXA) 
pQCT 
Distal Tibia Femur (1/3 Site) 
DXA 













a B one Mineral Density 
b Bone Mineral Content 
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Table 2: Characteristics of Subjects at Baseline 
ISU UC-Davis ISU+UC-Davis 
(n=122) (n=120) (N=242) 
Mean ± SD [min -max] 
Age (years) 54.0 ± 3.0 54.7 ± 3.5 54.3 ± 3.3 
[46.1 - 60.2] [45.8 - 65.0] [45.8 - 65.0] 
Years since menopause 3.4 ± 1.9 3.7 ± 2.1 3.5 ± 2.0 
[l.l - 8.0] [0.8 - 10.1] [0.8 - 10.1] 
Estrogen exposure (years) 37.4 ± 3.3 38.2 ± 3.4 37.8 ± 3.4 
[27.0 - 44.0] [28.0 - 48.0] [27.0 - 48.0] 
Race Number of subjects (%) 
Caucasian 120 (98.4) 84 (86.7) 224 (92.6) 
African American 1 (0.8) 2 (1.7) 3 (1.2) 
Native American 0 7 (0.8) 7 (0.4) 
Asian 0 3 (2.5) 3 (1.2) 
More than one race 1 (0.8) 6 (5) 7 (2.9) 
Unknown 0 2 (1.7) 2 (0.8) 
Not reported 0 2 (1.7) 2 (0.8) 
~k amily history of cardiovascular 
78 (63.9) 57 (47.5) 135 (55.8) 
disease 
Family history of osteoporosis 34 (27.9) 40 (33.3) 74 (30.6) 
•personal history of bone fracture 47 (38.5) 39 (32.5) 86 (35.5) 
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Table 2 (continued): Characteristics of Subjects at Baseline 
ISU UC-Davis ISU+UC-Davis 
(n=122) (n=120) (N=242) 
Past hormone therapy use`s Number of subjects (%) 
Estrogen+progestogen 55 (45.1) 43 (35.8) 98 (40.5) 
Estrogen 8 (6.6) 19 (15.8) 27 (11.2) 
Progestogen/progesterone 11 (9.0) 15 (12.5) 26 (10.7) 
Past hormone therapy useb(mos) Median [min -max] 
Estrogen+progestogen 12 12 12 
[0.3 - 120] [0.3 - 114] [03 - 120] 
Estrogen 15.5 12 12 
[ 1 - 60] [ 1 - 132] [ 1 - 132] 
Progestogen/progesterone 6 6 6 
[1 - 36] [1 - 24] [1 - 36] 
a Number and percentage of women who used hormone therapy. 
b Distributions for these variables were not normal and thus median [min -max] values are reported. 
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Table 3: Body Size and Body Composition at Baseline 
ISU UC-Davis ISU+UC-Davis 
Measnremerlt 
(n=122) (n=120) (N=242) 
Mean ± SD [min -max] 
Height (cm) 165.3 ± 6.0 164.2 ± 6.7 164.7 ± 6.4 
[ 150.6 - 178.4] [ 146.3 - 1.82.2] [ 146.3 - 182.2] 
Weight (kg) 68.0 ± 8.7 67.4 ± 10.0 67.7 ± 9.3 
[47.8 - 89.2] [43.7 - 94.5] [43.7 - 94.5] 
BMI (kg/m2) 24.9 ± 2.7 25.0 ± 3.4 25.0 ± 3.1 
[ 18.9 - 29.9] [ 17.8 - 32.7] [ 17.8 - 32.7] 
Waist circumference (cm) 76.7 ± 7.2 79.2 ± 8.5 77.9 ± 8.0 
[62.8 - 98.6] [59.1 - 100.6] [59.1 - 100.6] 
Hip circumference (cm) 102.0 ± 6.5 98.5 ± 6.7 100.3 ± 6.8 
[87.1 - 117.2] [80.9 - 118.2] [80.9 - 118.2] 
Waist-to-hip ratio 0.8 ± 0.1 0.8 ± 01 0.8 ± 0.1 
[0.6 - 0.9] [0.6 - 0.9] [0.6 - 0.9] 
Lean massy (kg) 43 ± 0.4 4.3 ± 0.5 4.3 ± 0.5 
[3.4 - 5.5] [3.0 - 5.6] [3.0 - 5.6] 
Fat massy (kg) 2.3 ± 0.6 2.3 ± 0.7 2.3 ± 0.6 
[d.8 - 3.7] [0.8 - 4.8] [0.8 - 4.8] 
Percent body fata (°Io) 34.7 ± 5.1 34.3 ± 6.2 34.5 ± 5.7 
[ 18.1 - 44.6] [ 18.4 - 56.0] [ 18.1 - 56.0] 




































































































































































































































































































































































































































































































































































Table 5: Circulating Analytes at Baseline: C-Reactive Protein (CRP), Total 
Homocysteine (Hcy), Folate, and Vitamin B12 
Median Normal Range Reported 
Circulating Variables
[min —max] from Literature 
Serum CRP (mg/L) 1.0 1.5`' 
[0.0001 - 29.9] 
Plasma total Hcy (µmol/L) 7.3 6.8 ± O.ld
[4.2 - 17.6] 
Intracellular folateb (ng/mL) 538.4 277.1 ± 4.6d
[249.3 — 2128.3] 
Serum folate (ng/mL) 13.3 12.9 ± 0.2d
[4.2 — 59.4] 
Serum vitamin B12 (pg/mL) 492.7 628.2e
[59.7 — 1567.4] [535.5 — 720.7] 
a Distributions for these variables were not normal and thus median [min, max] values are reported. 
b Values reported on 234 women as seven samples were incorrectly processed, one sample was missing, and 
two at ISU and two at UC-Davis were missing hematocrit values. 
Median value reported by Bassuk et al. (2004) for American women not on hormone therapy 
d Values reported are geometric means ± SE from NHANES 2001-2002 data for women (Ganj i and Kafai 
2006). 
e Value reported is mean [min -max] NHANES III data for women (Ganji and Kafai 2003). 
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Table 6: Dietary Intake Based on Semi-Quantitative Food Frequency Questionnaire 
ISU UC-Davis ISU+UC-Davis 
Nutrients
(n=122) (n=120) (N=242) 
Median [min-max] 
Energy (kcal/day) 1588 1422 1547 
[423 - 4564] [424 - 3633] [423 - 4564] 
--Carbohydrate (g/day) 195 162 176 
[33 - 476] [27 - 421] [27 - 476] 
Protein (g/day) 66 58 61 
[20 - 168] [ 15 - 143] [ 15 - 168] 
Total fat (g/day) 67 62 65 
[ 17 - 247] [22 - 164] [ 17 - 247] 
Saturated fat (g/day) 20 18 19 
[5 - 65] [5 - 53] [5 - 65] 
Monounsaturated fatty acids (g/day) 25 24 25 
[6 - 97] [7 - 65] [6 - 97] 
Polyunsaturated fatty acids (g/day) 16 16 16 
[3 - 70] [5 - 44] [3 - 70] 
Alcoholb'` (g/week) 28.1 53.3 43.0 
[0.7 - 302.4] [2.0 - 242.4] [0.6 - 302.4] 
[n=82] [n=100] [n=182] 
Fiber (g/day) 17 16 16 
[4 - 50] [6 - 42] [4 - 50] 
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Caffeineb'd (g/day) 224 217 219 
[0.3-842] [0.2-1392] [0.2-1392] 
[n=114] [n=114] [n=228] 
Vitamin A (N) 430 306 371 
[85 - 1590] [60 - 970] [60 - 1590] 
Vitamin E (a-TE) 9.2 10.0 9.5 
[1.9-37.5] [3.2-26.7] [1.9-37.5] 
Riboflavin (mg/day) 1.6 1.4 1.5 
[0.4 - 3.9] [0.3 - 3.2] [0.3 - 3.9] 
Vitamin B6 (mg/day) 1.7 1.5 1.5 
[0.4 - 4.6] [0.4 - 3.5] [0.4 - 4.6] 
Folic acid (µg/day) 322 326 324 
[78 - 1013] [112 - 918] [78 - 1013] 
Vitamin B12 (µg/day) 3.8 2.8 3.2 
[1.0 - 10.4] [0.4 - 8.3] [0.4 - 10.4] 
Magnesium 290 269 283 
[63 - 734] [68 - 664] [63 - 734] 
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Table 6 (continued): Dietary Intake Based on Semi-Quantitative Food Frequency 
Questionnaire 
ISU UC-Davis ISU+UC-Davis 
Nutrients
(n=122) (n=120) (N=242) 
Calcium Median [min -max] 
Dietary intake (mg/day) 762 634 686 
[ 152 - 2446] [ 154 - 1856] [ 152 - 2446] 
Supplemental intake (mg/day) 323 286 323 
[0 - 1130] [0 - 1130] [0 — 1130] 
Lifetime calcium intake from dairy productsb (mg/day) 
Childhood (5 — 11 years) 910 638 870 
[0 - 2964] [0 - 2607] [0 — 2964] 
Adolescence (12 - 18 years) 899 632 702 
[0 - 4118] [0 - 2281] [0 — 4118] 
Young adult (19 - 34 years) 641 398 561 
[0 - 2989] [0 - 2234] [0 — 2989] 
Midlife adult (35 — 49 years) 586 337 447 
[0 - 2409] [0 - 2234] [0 — 2409] 
Mature adulte (> 50 years) 606 282 403 
[0 - 1886] [0 - 1645] [0 — 1886] 
a Distributions for these variables were not normal and thus median [min -max] values are reported. 
b Reported from nutrition history questionnaire. 
Amount of alcohol is based on women who reported intake and does not include abstainers. 
d Amount of caffeine is based on women who reported intake and does not include abstainers. 
e Number of women who were > 50 years of age at baseline at ISU=108, at UC-Davis= l O5, and combined=213. 
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Table 7: Correlation Analysis: C-Reactive Protein (CRP) and Total Homocysteine 
(Hcy) versus Bone Measures 
CRP Total Hcy 
(mg/L) (µmoUL) 
r P r P 
Dual Energy X-Ray Absorptiometry n=233a n=242 
Total proximal femur BMC (g) 0.067 0.31 0.078 0.23 
Total proximal femur BMD (g/cm2) 0.192 0.003** 0.002 0.98 
Lumbar spine BMC (g) -0.065 0.32 0.051 0.43 
Lumbar spine BMD (g/cm2) 0.127 0.053 0.043 0.51 
Peripheral Quantitative Computed Tomography 
Distal tibia (trabecular) BMC (g) -O.OSSb 0.47 -0.041 0.58 
Distal tibia (trabecular) BMD (g/cm2) 0.178b 0.017* -0.06 0.42 
Femur (1/3 site; cortical) BMC (g) -0.120` 0.07 0.099 0.13 
Femur (1/3 site; cortical) BMD (g/cm2) -0.092` 0.17 0.036 0.58 
a 
N=228 for CRP as nine data points with a CRP value > l Omg/L were excluded. 
b 
N=178 for correlation between CRP and distal tibia (trabecular BMC and BMD) as 64 data points were not 
available either due to improper data acquisition of trabecular bone measurements or CRP value > 10mg/L. 
~ N=228 for correlation between CRP and 1/3 femur (cortical BMC and BMD) as five 1 /3 femur measurements 
were not available because UC-Davis institutional approval was not yet secured for scanning these women and 




Table 8: Regression Analysis: Contributors to Volumetric Bone Mineral Content 
Trabecular Bone Mineral Content at the Distal Tibias











Intercept 77.0460 0.016 
Study site 1.8739 0.001 0.62 1.23 
Weight 0.2028 12.37 <_0.0001 1.04 
Hemoglobin 6.7740 5.54 0.0006 1.16 
Serum uric acid -5.3385 4.17 0.0027 1.19 
Serum glucose -0.4056 1.48 0.071 1.21 
Cortical Bone Mineral Content at the Femur (1/3 site)e












Intercept 378.8962 <_0.0001 
Study site 20.5374 8.65 _<0.0001 1.01 
Weight 0.6947 3.48 0.0024 1.01 
Age -1.9596 3.33 0.0030 1.00 
Additional variables included in the trabecular bone mineral content model: age, total Hcy, CRP, total calcium, 
and dietary calcium. Additional variables included in the cortical bone mineral content model: blood glucose, 
hemoglobin, serum uric acid, total Hcy, CRP, total calcium, and dietary calcium. 
a N=62 for the trabecular bone mineral content model as 58 measurements were not available due to improper 
data acquisition. 
b Squared semi-partial Type II correlation coefficient; accounts for shared variance among variables. 
Variables (except site) left in the model are significant at p<_0.101evel. 
a Measures inflation in the variances of parameter estimates due to multicollinearities among regressors. 
e N=237 for cortical bone mineral content model as five measurements were not available because UC-Davis 
institutional approval was not yet secured for scanning these women. 
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Table 9: Regression Analysis: Contributors to Cardiovascular Disease Risk Factors 
Total I~omocysteine 






b Prob > ~t~ 
Variance 
Inflation Factor 
Intercept 6.0234 <_0.0001 
Study site 0.2962 0.01 0.23 1.00 
Serum vitamin B 12 -0.003 2 11.81 <_0.0001 1.00 
Serum creatinine 3.9617 5.84 <_0.0001 1.00 
Serum C-Reactive Protein 






Prob > ~t~ b
Variance 
Inflation Factor` 
Intercept -3796.1226 <_0.0001 
Study site -5.4312 0.00 0.98 1.12 
Whole body percent fat 77.5817 4.93 <0.0001 1.18 
Serum uric acid 311.8754 2.96 0.0029 1.22 
Serum triglycerides 8.3998 2.86 0.0034 1.23 
White blood cell count 270.6307 1.93 0.016 1.19 
Serum iron -8.4490 1.79 0.019 1..03 
Additional variables included in total Hcy model: Serum or intracellular folate, serum uric acid, dietary factors 
important for Hcy metabolism. Additional variables included in CRP model: Age, waist circumference, TIBC, 
total cholesterol/HDL-C ratio. 
a Squared semi-partial Type II correlation coefficient; accounts for shared variance among variables. 
b Variables (except study site) left in the model are significant at p<_0.10 level. 
Measures inflation in the variances of parameter estimates due to multicollinearities among regressors. 
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Figure 2: Change in circulating analytes in postmenopausal women from baseline 
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Figure 2 (continued): Change in circulating analytes in postmenopausal women from 
baseline through one year. 
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GENERAL CONCLUSIONS 
In summary, the results from our primary objective of this study suggest that Hcy and 
CRP are not related to trabecular or cortical bone in healthy, non-osteoporotic 
postmenopausal women. Since a vast majority of these women did not have elevated Hcy, we 
were not able to determine whether or not hyperhomocysteinemia was related to trabecular 
bone. Future studies should be conducted to establish which type of bone is primarily lost 
with hyperhomocysteinemia. In women with elevated CRP (> 1.8 mg/L), lumbar spine BMD 
was inversely related to CRP, but this relationship needs to be further explored in 
epidemiological and intervention studies. The results from the secondary objective 
determined that weight, hemoglobin, and serum uric acid contributed to about 22% of the 
variability in trabecular BMC. In contrast, study site, weight, and age were the significant 
contributors to cortical BMC. Serum vitamin B 12 and serum creatinine contributed to the 
variability (~19%) in total Hcy, indicating that renal function is important in Hcy 
metabolism. Serum iron contributed inversely to CRP, but whole body percent fat, serum uric 
acid, triglycerides, and white blood cell count were positively related to circulating CRP. 
Hepcidin, a key regulator of serum iron during inflammation, is thought to disable iron efflux 
from cells, thereby making iron less available for invading microorganisms. This may 
explain the inverse association between serum iron concentration and CRP. Since 
hemoglobin was a significant contributor to trabecular BMC, while iron was a significant 
contributor to CRP, it is possible that inflammation may mediate the relationship between 
low iron status (reflected by low serum iron and/or hemoglobin concentration) and low 
trabecular BMC. Results from the third objective demonstrate that total Hcy and CRP 
significantly increased at the end of one year, while serum folate and vitamin B 12 decreased 
significantly. Future data analyses will be conducted to determine the effect of two doses of 
soy isoflavones (80 and 120 mg) on circulating total Hcy and CRP in relation to change in 
trabecular and cortical bone and in relation to CVD risk. 
